

B-1/1018, VASANT KUNJ, NEW DELHI - 110 070 TELEPHONE : 011-41082626 EMAIL : rohit_mehra@rnaca.in rnaca1@gmail.com

Independent Auditor's Report

To the Members of Yatharth Hospital & Trauma Care Services Limited (Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

Report on the Audit of the Consolidated Indian Accounting Standards (Ind AS) Financial Statements

Opinion

We have audited the accompanying Consolidated Ind AS financial statements of Yatharth Hospital & Trauma Care Services Limited (Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.) (hereinafter referred to as "the Holding Company"), and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") comprising of the Consolidated Balance Sheet as at 31st March 2023, the Consolidated Statement of Profit & Loss (including Other Comprehensive Income), the Consolidated Cash Flow Statement and the Consolidated Statement of Changes in Equity for the year then ended and a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the consolidated Ind AS financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Group as at March 31, 2023 and its profit, total comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Ind AS financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the consolidated Ind AS financial statement.

Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexures to Board's Report, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the consolidated Ind AS financial statements, standalone Ind AS financial statements and our auditor's report thereon.

Our opinion on the consolidated Ind AS financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated Ind AS financial statements, our responsibility is to read the other information, consider whether the other information is materially inconsistent with the consolidated Ind AS financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibility of Management for the Consolidated Ind AS Financial Statements

The Holding Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these consolidated Ind AS financial statements that give a true and fair view of the consolidated financial position, consolidated financial performance, consolidated changes in equity, and consolidated cash flows of the Holding Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. The respective Boards of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated Ind AS financial statements by the Directors of the Company, as aforesaid.

In preparing the consolidated Ind AS financial statements, management is responsible for assessing the Holding Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of directors management either intends to liquidate the Holding Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Holding company's financial reporting process of the Group..

Auditor's Responsibility for the Audit of the Consolidated Ind AS Financial Statements Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated Ind AS financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Holding Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Holding Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities within the Group to express an opinion on the consolidated financial statements.

Materiality is the magnitude of misstatements in the consolidated financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the consolidated financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the consolidated financial statements.

We communicate with those charged with governance of the Company and such other entities included in the consolidated financial statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

1. We did not audit the financial statements of 3 (Three) subsidiaries namely AKS Medical & Research Centre Private Limited, Ramraja Multispeciality Hospital & Trauma Centre Pvt Ltd and Sanskar Medica India Limited whose financial statements reflect total assets of Rs.2,196.78 Millions as at 31st March 2023, total revenues of Rs.1,497.75 Millions for the year then ended on that date, as considered in the consolidated financial statements.

These financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, and our report in terms of sub-sections (3) and (11) of Section 143 of the Act, insofar as it relates to the aforesaid subsidiaries is based solely on the reports of the other auditors.

Our opinion on the consolidated financial statements, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial statements/financial information certified by the Management.

Report on Other Legal and Regulatory Requirements

- 1. As required by Section 143 (3) of the Act, we report that:
- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated Ind AS financial statements.
- (b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated Ind AS financial statements have been kept so far as it appears from our examination of those books and the reports of the other auditors.
- (c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss, the Consolidated Statement of Changes in Equity and the Consolidated Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated Ind AS financial statements.

- (d) In our opinion, the aforesaid consolidated Ind AS financial statements comply with the Indian Accounting Standards prescribed under Section 133 of the Act.
- (e) On the basis of the written representations received from the directors of the Holding Company as on 31st March, 2023 taken on record by the Board of Directors of the Holding Company and the reports of the statutory auditors of its subsidiary companies, none of the directors of the Group companies, is disqualified as on 31st March, 2023 from being appointed as a director in terms of Section 164 (2) of the Act.
- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A" which is based on the auditors' reports of the Company and its subsidiary companies. Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended:
 In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.
- (h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Consolidated Ind AS Financial statement disclose the impact of pending litigations on the consolidated financial position of the group Refer Note 38 to the consolidated Ind AS financial statements.
 - ii. The Group does not have any material foreseeable losses in respect of any long-term contracts including derivative contracts;
 - iii. There are no amounts that were due for being transferred to the Investor Education and Protection Fund by the Holding Company and subsidiary companies.
 - iv. (a) The respective Managements of the Company and its subsidiaries which are companies incorporated in India, whose financial statements have been audited under the Act, have represented to us that, to the best of their knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company or any of such subsidiaries to or in any other person or entity, including foreign entity ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company or any of such subsidiaries ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

- (b) The respective Managements of the Company and its subsidiaries which are companies incorporated in India, whose financial statements have been audited under the Act, have represented to us that, to the best of their knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company or any of such subsidiaries from any person or entity, including foreign entity ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company or any of such subsidiaries shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- (c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances performed by us on the Company and its subsidiaries which are companies incorporated in India whose financial statements have been audited under the Act, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
- v. The company has not declared or paid any dividend during the year
- vi. Proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 for maintaining books of account using accounting software which has a feature of recording audit trail (edit log) facility is applicable to the Company and its subsidiaries with effect from April 1, 2023, and accordingly, reporting under Rule 11(g) of Companies (Audit and Auditors) Rules, 2014 is not applicable for the financial year ended March 31, 2023.
- 2. With respect to the matters specified in paragraphs 3(xxi) and 4 of the Companies (Auditor's Report) Order, 2020 (the "Order"/ "CARO") issued by the Central Government in terms of Section 143(11) of the Act, to be included in the Auditor's report, according to the information and explanations given to us, and based on the CARO reports issued by us for the Company and its subsidiaries included in the consolidated financial statements of the Company, to which reporting under CARO is applicable, we report that there are no qualifications or adverse remarks in these CARO reports.

New Delki

For R. NAGPAL ASSOCIATES

Chartered Accountants

Firm Registration No. 002626N

bil Mil

(CA ROHIT MEHRA)

Partner

Membership No. 093910 UDIN:23093910BGUFVU9045

Place: Noida Dated: 17.06.2023

ANNEXURE "A" TO THE INDEPENDENT AUDITOR'S REPORT

(Referred to in paragraph 1(f) under 'Report on Other Legal and Regulatory Requirements' of our report to the Members of Yatharth Hospital & Trauma Care Services Limited (Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.) of even date)

Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

In conjunction with our audit of the consolidated Ind AS financial statements of the Company as of and for the year ended March 31, 2023, we have audited the internal financial controls over financial reporting of Yatharth Hospital & Trauma Care Services Limited (Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.) (hereinafter referred to as the "Company") and its subsidiary companies, which are companies incorporated in India, as of that date.

Management's Responsibility for Internal Financial Controls

The respective Boards of Directors of the Company and its subsidiary companies, which are companies incorporated in India, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the respective Companies considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "ICAI"). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company and its subsidiary companies, which are companies incorporated in India, based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India ("ICAI") and the Standards on Auditing, prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting of the Company and its subsidiary companies, which are companies incorporated in India.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2023, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For R. NAGPAL ASSOCIATES
Chartered Accountants

Firm Registration No. 002626N

agpal Ass

(CA ROHIT MEHRA)

Membership No. 093910

UDIN:23093910BGUFVU9045

Place: Noida Dated: 17.06.2023

(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)
CIN:U85110DL2008PLC174706

(Rohit Mehra) Partner M. No. 093910 Place: Noida Dated: 17/06/2023

Consolidated Balance Sheet as at March 31, 2023

(All amounts in million, unless otherwise stated)

	Particulars	Note No.	As at March 31, 2023	As at March 31, 2022
	ASSETS			
	Non-current assets	2	2,553.09	2,577.81
(a)		2 3	2,333.09	0.07
(b)	Intangible Assets	3		-
(c) (d)	Capital work in progress Right-of-use of assets	30	35.12	56.12
(e)	Goodwill	46	397.01	397.01
(f)	Financial Assets			
- 404	(i) Other Financial Assets	4	19.56	22.25
(g)	Deferred Tax Assets (Net)	16	82.79	54.53
(h)		5	9.41 3,096.98	58.45 3,166.23
	Total non-current assets		3,090.98	3,100.23
	Current assets	6	60.70	51.95
(a)	Inventories Financial Assets	o o	00.70	51.75
(b)	(i) Trade receivables	7	1,076.44	855.38
	(ii)Cash and cash equivalents	8	374.32	117.07
	(iii) Bank Balance other than (ii) above	9	10.11	3.74
(c)		10	111.78	30.23
(d)		11	129.31	35.63
	Total current assets		1,762.67	1,094.00
	Total Assets		4,859.66	4,260.23
	EQUITY AND LIABILITIES Equity			
(a)		12	655.17	655.17
	Other Equity	13	1,174.47	513.68
	Equity attributable to the owners of the company		1,829.64	1,168.85
	Non-controlling interest		1,829.64	1,168.85
	Total Equity			
(a)	Non-current liabilities Financial liabilities			
(21)	(i) Borrowings	14	2,005.94	2,073.82
	(ii) Lease Liabilities	30	15.91	36.74
(b)	Provisions	15	12.99	9.78
	Deferred tax liabilities (Net)	16	-	
(€)	Total non-current liabilities		2,034.84	2,120.34
I	Current liabilities			
(a)	Financial liabilities	17	631.82	508.00
	(i) Borrowings	30	20.45	19.12
	(ii) Lease Liabilities	18		
	(iii) Trade payables	10	15.08	22.8
	(a) Total outstanding dues of Micro Enterprises and Small Enterprises (b) Total outstanding dues of creditors other than Micro Enterprises and Small Enterprises		153.69	181.31
		19	142.40	145.30
	(iv) Other financial liabilities	20	31.15	
	Other current liabilities		0.59	
(c)	Provisions	21	995.18	
	Total Equity and Liabilities		4,859.66	
Ç	nmary of significant accounting policies	1.3		
	e note nos. I to 52 are integral part of the standalone financial statements.			
As	per our report of even date			
For	r R.Nagpal Associates		of the Board of Director	
CH	ARTERED ACCOUNTANTS		Hospital & Trauma Care	e Services Limited
Fin	m Registration No.002626N	CIN:U8511	0DL2008PLC174706	
	agpal Assoc	N	2. Trauma	Mill
	200		0	52/11/11/11
1	1 / 1 / 1 / 2 / 1 / 2 / 1 / 2 / 1 / 2 / 1 / 2 / 1 / 2 / 2	Da Alan I	Kumar Tyagi	Dr. Kapil Kumar
	ohit Mehra) New Delhi		Whole-Time Director	Managing Director
	rtner (C)	DIN:01792	gambons .	DIN; 01818736
	No. 093910	Dittollion	12	(8) 10

CFO

PAN: AGFPP2937A

Ritesh Mishra CS & Compliance Officer

M. No 51166

(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Consolidated Statement of Profit & Loss for the year ended 31 March, 2023

(All amounts in million, unless otherwise stated)

	Particulars	Note No	For the year ended March 31, 2023	For the year ended March 31, 2022
	Income			
I	Revenue from operations	22	5,202.93	4,009.37
11	Other income	23	28.07	16.49
Ш	Total income (I+II)		5,231.00	4,025.86
13.7	F			*
IV	Expenses: Cost of Material Consumed	24	929.35	813.28
	Employee benefits expense	25	919.30	804.68
	Finance cost	26	213.87	214.86
	Depreciation and amortization expenses	27	275.07	278.68
	Other expenses	28	2,016.63	1,283.29
	Total expenses	20	4,354.22	3,394.80
V	Profit / (Loss) before tax (III-IV)		876.78	631.06
VI	Tax expense:		070170	001.00
* 1	(1) Current tax		246.66	180.09
	(2) Income tax of earlier years		1.61	-
	(3)MAT credit availed/reversed		11.03	18.02
	(4) Deferred tax (net)		(40.19)	(8.68)
	Total tax expenses		219.10	189.44
VII	Profit/(Loss) for the year (V-VI)	,	657.68	441.62
VIII	Other comprehensive income	,		
	(a)(i) Items that will not be reclassified to profit or loss		2	-
	(ii)Income tax relating to items that will not be reclassified to profit or loss			-
	(b) (i) Items that will be reclassified to profit or loss		4.01	. 3.77
	(ii)Income tax relating to items that will be reclassified to profit or loss		(0.90)	. (1.10)
	Other comprehensive income for the year		3.11	2.67
IX	Total comprehensive income (VII+VIII)(Comprising Profit/ (Loss) and Other Comprehensive Income for the year)		660.79	444.30
	Profit/(Loss) for the year attributable to			
	To the Owners of the company		657.68	441.62
	Non Controlling Interest			-
	Other comprehensive income for the year attributable to:			
	To the Owners of the company		3.11	2.67
	Non Controlling Interest		~	2
	Total Comprehensive Income for the year attributable to:		50.00	000000000000000000000000000000000000000
	To the Owners of the company		660.78	444.30
X	Non Controlling Interest Earnings per equity share - Rs		-	-
Α.	(1) Basic	29	10.09	6.78
	(2) Diluted		10.09	6.78
Summa	rry of significant accounting policies	1.3		
Summe	ry of significant accounting poncies	1.3		

The note nos. 1 to 52 are integral part of the standalone financial statements.

agpal Asso

New Delhi

As per our report of even date

For R.Nagpal Associates CHARTERED ACCOUNTANTS

Firm Registration No.002626N

(Rohit Mehra) Partner

M. No. 093910 Place: Noida

Dated: 17/06/2023

On behalf of the Board of Directors Yatharth Hospital & Trauma Care Services Limited CIN:U85110DL2008PLC174706

Dr. Ajay Kumar Tyagi Chairman & Whole-Time Director

DIN:01792886

CS & Compliance Officer M. No 51166

Dr. Kapil Kumar Managing Director

DIN: 01818736

Pankaj Prabhakar CFO

PAN: AGFPP2937A

(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Consolidated Statement of Cash Flow for the Year ended 31 March, 2023

(All amounts in million, unless otherwise stated)

	Particulars	For the year ended March 31, 2023	For the year ended March 31, 2022
A.	Cash flow from operating activities		
	Profit/(Loss) before tax and exceptional items	876.78	631.06
	Adjustments for:		
	Depreciation and Amortisation expense	275.07	278.68
	Finance costs	213.87	214.86
	Interest on bank deposits	(1.41)	(1.02)
	Operating profit before working capital changes	1,364,30	1,123.58
	Working capital adjustments		1,120,50
	(Increase)/Decrease in Trade receivables	(221.06)	(487.73)
	(Increase)/Decrease in Inventories	(8.74)	(18.06)
	(Increase)/Decrease in Financial Assets and other Current and Non-Current Assets	(91.01)	25.26
	Increase (Decrease) in Financial Liabilities & Other Current and Non-Current Liabilities	(39.43)	73.36
	Increase (Decrease) in Current and Non current Provisions	7.75	13.14
	Cash generated from operations	1,011.81	729.56
	Income tax (paid)/Refund (net)	(373.98)	(130.21)
	Net cash inflow from operating activities'A'	637.84	599.35
B.	Cash flow from Investing activities		
	Purchase of Property, plant and equipment including capital work in progress and capital advances and capital creditors	(198.14)	(131.34)
	Acquistion of Fixed Assets-Net of Liabilities On account of Business Combination	-	(262.30)
	Investment in Subsidiary	2	(126.91)
	Interest on Bank deposits	1.41	1.02
	Investment in bank deposits having original maturity of more than three months	(6.37)	(2.22)
	Net cash used in investing activities'B'	(203,10)	(521.75)
C	Cash flow from Financing activities		
	Net movement of long term borrowings and short term borrowings		
	Finance Cost	36.39	203.62
	Titialice Cost	(213.87)	(214.86)
	Net cash used in financing activities'C'	(177.48)	(11.24)
	Net increase/(Decrease) in cash or cash equivalent (A+B+C)	257.25	66.37
	Cash & cash equivalent at the commencement of the year	117.07	
	Add: On account of Business Combination	117.07	50.00
	Cash & cash equivalent at the end of the year	274.22	0.71
	Reconciliation of cash and cash equivalents as per the cash flow statement	374.32	117.07
	Balance with banks in current accounts	254.00	,
	Cash in hand	356.80	113.64
	Bank Deposits with maturing with in 3 months- pledged with banks	15.45 2.08	2.93
	Total	374,32	0.51
		374.32	117.07
	Significant Accounting Policies 1.	3	

The accompanying notes are integral part of the financial statements.

agpal Assoc

New Delhi

Tered Account

As per our report of even date attached to the financial statement

21 57 h

For R.Nagpal Associates

CHARTERED ACCOUNTANTS

Firm Registration No.002626N

(Rohit Mehra) Partner M. No. 093910

Place: Noida Dated. 17/06/2023 On behalf of the Board of Directors

Yatharth Hospital & Trauma Care Services Limited

CIN:U85110DL2008PLC174706

Dr. Ajay Kumar Tyagi Chairman & Whole-Time Director

DIN:01792886 DIN: 01818736

Traum

CS & Compliance Officer M. No 51166

Pankaj Prabhakar CFO

Dr. Kapit-Kumar

Managing Director

PAN: AGFPP2937A

(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.) CIN:U85110DL2008PLC174706

Consolidated Statement of changes in Equity for the year ended 31 March, 2023

(All amounts in million, unless otherwise stated)

Equity Share Capital:

P. d. I	As at March	31, 2023	As at March 31, 2022		
Particulars	Number of Shares	Amount	Number of Shares	Amount	
Shares outstanding at the beginning of the reporting year	65.52	655.17	16.38	163.79	
Change in equity share capital during the year	172.0000000		49.14	491.38	
Share outstanding at the end of the year	65.52	655.17	65.52	655.17	

Other Equity:

Particulars	Securities Premium Account	Retained Earnings	Other Comprehensive Income	Equity attributable to shareholders of the company	Equity attributable to Non Controlling Interest	Total Equity
Balance at 1st April, 2021	176.60	384.13	0.02	560.76	82.28	643.04
Surplus in the statement of profit and loss transferred during the year		441.62		441.62		441.62
Movement on account of equity purchase by Company	-	2	-	-	(82.28)	(82.28)
Restated Balances at the closing of the year	176.60	825.76	0.02	1,002.38	-	1,002.38
Issue of Bonus Shares	(176.60)	(314.77)	5000000	(491.38)		(491.38)
Total Comphensive Income for the current year	-	- 1	2.67	2.67		2.67
Balance at 31st March, 2022	-	510.98	2.70	513.68	-	513.68

Particulars	Securities Premium Account	Retained Earnings	Other Comprehensive Income	Equity attributable to shareholders of the company	Equity attributable to Non Controlling Interest	Total Equity
Balance at 1st April, 2022		510.98	2.70	513.68		513.68
Surplus in the statement of profit and loss transferred during the year		657.68	1 5 .00	657.68	-	657.68
Restated Balances at the closing of the year		1,168.66	2.70	1,171.36	_	1,171.36
Issue of Bonus Shares		-		20	- 1	-
Total Comphensive Income for the current year		-	3.11	3.11		3.11
Balance at 31st March, 2023	-	1,168.66	5.81	1,174.47	-	1,174.47

For Reserves see Note No-13

Significant Accounting Policies

The accompanying notes are integral part of the financial statements.

As per our report of even date attached to the financial statement

agpal Assoc

New Delhi

ered Account

For R.Nagpal Associates

Chartered Accountants Firm Registration No. 002626N

(Robit Mehra) Partner M. No. 093910

Dated: 17/06/2023

Place: Noida

1.3

For and on behalf of the Board

Yatharth Hospital & Trauma Care Services Limited

(rauma

Dr. Ajay Kumar Tyagi Chairman & Whole-Pime Director

DIN:01792886

Dr. Kapil Kumar Managing Director DIN: 01818736

Ritesh Mishra CS & Compliance Officer

M. No 51166

Pankaj Prabhakar

CFO

PAN: AGFPP2937A

CIN: U85110DL2008PLC174706

Notes to Consolidated Financial Statements

1. General Information

1.1 About the company

Yatharth Hospital & Trauma Care Services Limited ("The Company") (Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.) was incorporated in New Delhi on 28th February 2008. The Company has its registered office at JA, 108 DLF, Tower A, Jasola District, Centre South Delhi 110025. The company has its corporate office at Sector 1, Greater Noida (West), Uttar Pradesh 201308.

The Group is primarily involved in the business of providing healthcare services, operating hospitals and other allied services, as may be required for the provision of healthcare services.

1.2 Basis of preparation

a) Basis of preparation of financial statements:

The Consolidated Financial Statements have been prepared in accordance with the Indian accounting standard (Ind AS), notified under section 133 of the Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time. The Group has adopted all the applicable Ind AS. The Consolidated Financial Statements have been prepared on accrual and going concern basis. The accounting policies are applied consistently to all the periods presented in the financial statements. The Group has decided to round off the figures to the nearest Millions.

The Company consolidates its subsidiaries and other company in which it exercises control (referred to as Consolidated Companies). Subsidiaries are entities where the group exercises or controls more than one half of its total share capital. The net assets and results of acquired businesses are included in the consolidated financial statements from their respective dates of acquisition, being the date on which the Group obtains control. The results of disposed businesses are included in the consolidated financial statements up to their date of disposal, being the date on which control ceases.

The Consolidated Financial Statements have been prepared using uniform accounting policies for like transactions and other events in similar circumstances. The accounting policies adopted in the preparation of financial statements are consistent with those of previous year. The financial statement of the Company with those of the Companies consolidated have been combined on a line by line basis by adding together the book



CIN: U85110DL2008PLC174706

Notes to Consolidated Financial Statements

values of like items of assets, liabilities, income and expenses, after eliminating intra group balances, intra group transactions and the unrealised profits / losses, unless cost / revenue cannot be recovered.

The excess of cost to the Group of its investment, on the acquisition dates over and above the Group's share of equity in the Companies Consolidated, is recognised as Goodwill on Consolidation being an asset in the consolidated financial statements. The said Goodwill is not amortised, however, it is tested for impairment as at each Balance Sheet date and the impairment loss, if any, is provided for. On the other hand, where the share of equity in Companies consolidated as on the date of investment is in excess of cost of investments of the Group, it is recognised as Capital Reserve and shown under the head Other Equity in the Consolidated Financial Statements.

Investment in Associates is accounted for in Consolidated Financial Statements as per Equity method as per Ind AS 28 - Investments in Associates and Joint Ventures.

Non controlling interests in the net assets of Companies consolidated is identified and presented in the Consolidated Balance Sheet separately within equity. Non controlling interests in the net assets of Consolidated companies consists of:

- (a) The amount of equity attributable to non controlling interests at the date on which investment is made; and
- (b) The non controlling interests share of movements in equity since the date parent subsidiary relationship came into existence.

The Profit and other comprehensive income attributable to non controlling interests are shown separately in the Consolidated Statement of Profit and Loss.

The Consolidated Financial Information includes the financial information of Yatharth Hospital & Trauma Care Services Private Limited and its subsidiaries as set out below:

	Country of	Year ended		
Name of Company	Country of Incorporation	March 31,	March 31,	
552 559	incorporation	2023	2022	
AKS Medical & Research Centre Pvt.	India	100%	100%	
Ltd.		100%	100%	
Sanskar Medica India Limited	India	100%	100%	
Ramraja Multispeciality Hospital &	India	100%	100%	
Trauma Centre Private Limited		10070	10070	





Notes to Consolidated Financial Statements

Use of estimates and judgements:

The preparation of consolidated financial statements requires management to make judgements, estimates and assumptions in the application of accounting policies that affect the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Continuous evaluation is done on the estimation and judgements based on historical experience and other factors, including expectations of future events that are believed to be reasonable. Revisions to accounting estimates are recognised prospectively.

1.3 Summary of Significant accounting policies

1.3.1 Revenue Recognition

Revenue from operations

The Group's revenue from medical and healthcare services comprises of income from hospital services and sale ofpharmacy items.

Revenue from contracts with customers is recognised when control of the goods or services are transferred to thecustomer at an amount that reflects the consideration to which the company expects to be entitled in exchange for thosegoods or services.

Income from hospital services comprises of fees charged for inpatient and outpatient hospital services. Theperformance obligations for this stream of revenue include accommodation, surgery, medical/clinical professionalservices, food and beverages, investigations and supply of pharmaceutical and related products.

Revenue is measured based on the transaction price, which is the fixed consideration adjusted for components of variable consideration which constitutes discounts, estimated disallowances and any other rights and obligations asspecified in the contract with the customer. Revenue also excludes taxes collected (if any) from customers and deposited back to the respective statutory authorities.

Revenue is recognised at the point in time for the outpatient hospital services when the related services are rendered at the transaction price. With respect to the inpatients hospital services the revenue is recognized at the transaction price on such patients where the hospital services are rendered completely.

Revenue from sale of pharmacy and food and beverages (other than hospital services), where the performanceobligation is satisfied at a point in time, is recognised when the control of goods is transferred to the customer.



CIN: U85110DL2008PLC174706

Notes to Consolidated Financial Statements

The company applies the most likely amount method or the expected value method to estimate the variable consideration in the contract. The selected method that best predicts the amount of variable consideration is primarily driven by thenumber of volume thresholds contained in the contract. The most likely amount is used for those contracts with a singlevolume threshold, while the expected value method is used for those with more than one volume threshold. The company then applies the requirements on constraining estimates in order to determine the amount of variable consideration thatcan be included in the transaction price and recognised as revenue.

Contract assets represents value to the extent of medical and healthcare services rendered to the patients who areundergoing treatment/ observation on the balance sheet date and is not billed as at the balance sheet date.

Other Income

Interest on deposits, loans and debt instruments are measured at amortized cost. Interest income is recorded using the Effective Interest Rate (EIR). EIR is the rate that exactly discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the gross carrying amount of the financial asset or to the amortized cost of a financial liability. Other Income includes rental income, being recognized on due basis and sale at cafe and canteen to employee and others; which is recognized at a point of sale.

1.3.2 Property, Plant and Equipment

Property, Plant and Equipment (PPE) are stated at original cost of acquisition including incidental expenses and all the borrowing costs, which are directly attributable to the acquisition of assets and installation of the concerned assets. PPE are shown net of accumulated depreciation.

The Company has elected to continue with the carrying value for all of its Property, Plant and Equipment recognised as of April 01, 2018 (date of transition to Ind AS) measured as per the previous GAAP and used that carrying value as itsdeemed cost as at the date of transition.

Capital work in progress is stated at cost, net of accumulated impairment loss, if any.

Depreciation has been charged as per new rules as provided by The Companies Act, 2013. For PPE acquired during the year, depreciation is provided on pro rata basis from the date the assets were put to use. The carrying amount of a property, plant and equipment is de-recognised when





CIN: U85110DL2008PLC174706

Notes to Consolidated Financial Statements

no future economic benefits are expected from its use or on disposal. Assets taken on long term lease are amortized over the balance period of lease.

Depreciation on property, plant and equipment is provided on written down value method based on estimated useful life of assets as prescribed in part C of schedule II to the Companies Act, 2013.

Assets	Useful Life
Building	60 Years
Plant and Machinery	5-15 years
Furniture and Fittings	8 years
Air-conditoners	10 years
Electric installations	10 years
Office Equipments	5 years
Vehicles	8 years
Computers	3 years

The property, plant and equipment acquired under finance leases, if any, is depreciated over the asset's useful life or over the shorter of the asset's useful life and the lease term if there is no reasonable certainty that the Company will obtain ownership at the end of the lease term.

Freehold land is not depreciated. Lease hold land is depreciated over the balance period of lease, once the building or any other asset erected over such period of land is put to use.

Based on the planned usage of certain specific assets and technical assessment, the management has estimated theuseful lives of Property, plant and equipment as below:

- Individual asset not exceeding Rs. 5,000 have been fully depreciated in the year of purchase.
- Leasehold improvements are amortised over the period of the lease or estimated useful life, whichever is shorter.



CIN: U85110DL2008PLC174706

Notes to Consolidated Financial Statements

agpal Asso

The residual values, useful lives, and methods of depreciation of property, plant and equipment are reviewed at eachfinancial year end and adjusted prospectively, if appropriate.

1.3.3 Taxes on Income

Tax Expenses:

Income Tax expense comprises of current tax and deferred tax charge or credit. Provision for current tax is made with reference to taxable income computed for the financial year for which the financial statements are prepared by applying the tax rates as applicable.

Current Tax-Current Income tax relating to items recognized outside the profit and loss is recognized outside the profit and loss (either in other comprehensive income or in other component of equity)

MAT- Minimum Alternate Tax (MAT) paid in a year is charged to the Statement of Profit and Loss as current tax. The company recognizes MAT credit available as an asset only to the extent there is convincing evidence that the company will pay normal income tax during the specified period, i.e., the period for which MAT Credit is allowed to be carried forward. In the year in which the Company recognizes MAT Credit as an asset in accordance with the Guidance Note on Accounting for Credit Available in respect of Minimum Alternate Tax under the Income Tax Act, 1961, the said asset is created by way of credit to the statement of Profit and Loss and shown as "MAT Credit Entitlement." The Company reviews the "MAT Credit Entitlement" asset at each reporting date and writes down the asset to the extent the company does not have convincing evidence that it will pay normal tax during the sufficient period.

Deferred Tax:-Deferred tax is provided using the liability method on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purpose at reporting date i.e. timing difference between taxable income and accounting income. Deferred income tax assets and liabilities are measured using tax rates and tax laws that have been enacted or substantively enacted by the balance sheet date and are expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of changes in tax rates on deferred income tax assets and liabilities is recognized as income or expense in the period that includes the enactment or the substantive enactment date. A deferred income tax asset is recognized to the extent that it is probable that future taxable profit will be available against which the deductible temporary differences and tax losses can be utilized.

The carrying amount of deferred tax assets is reviewed as at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profit will not be available against which deferred tax asset to be utilized. Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Notes to Consolidated Financial Statements

Deferred tax assets are recognized for the unused tax credit to the extent that it is probable that taxable profits will be available against which the losses will be utilized. Significant management judgement is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits.

Deferred tax relating to items recognised outside profit or loss is recognised outside profit or loss (either in othercomprehensive income or in equity). Deferred tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity.

1.3.4 Borrowing Costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes asubstantial period of time to get ready for its intended use or sale are capitalised as part of the cost of the asset. Allother borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

1.3.5 Leases

Right to Use Assets

The Company recognizes a right-to-use asset, on a lease by-lease basis, to measure that right-to-use asset an amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments relating to that lease recognised in the balance sheet immediately beforethe date of initial application.

The cost of right-of-use assets includes the amount of lease liabilities recognised. Initial direct costs incurred andlease payments made at or before the commencementdate less any lease incentives received, the recognized right-of-use assets are depreciated on a straight-linebasis over the shorter of its estimated useful life and thelease term. Right-of-use assets are subject to impairmenttest.

Lease Liabilities

The Company recognise a lease liability at the presentvalue of the remaining lease payments, discounted using the lessee's incremental borrowing rate. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on alease by lease basis In calculating the present value of lease payments, the Company uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable.

Notes to Consolidated Financial Statements

Short-term Leases and leases of low-value assets

The company applies the short-term lease recognition exemption to its short-term leases (i.e., those leasesthat have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets recognition exemption to leases that are considered of low value. Lease payments on short-term leases and leases of low-value assets are recognised as expense on a straight-line basis over the lease term.

1.3.6 Inventory

Inventories are stated at lower of cost or net realisable value. Cost of Inventories comprises of cost of purchase, cost of conversion and other costs incurred in bringing the inventories to their present location and condition. Closing stock cost is determined on FIFO basis

1.3.7 Employee Benefits

The undiscounted amount of short-term employee benefits i.e. wages and salaries, bonus, incentive andannual leave etc. expected to be paid in exchange for the service rendered by employees are recognized as an expense except in so far as employment costs may be included within the cost of an asset during the period when the employee renders the services.

Retirement benefit in the form of provident fund and pension contribution is a defined contribution schemeand is recognized as an expense except in so far as employment costs may be included within the cost of anasset.

Gratuity is a defined benefit obligation. The liability is provided for on the basis of actuarial valuation made at the end of each financial year. The actuarial valuation is done as per Projected Unit Credit method.

Re-measurements, comprising of actuarial gains and losses, the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability and the return on plan assets (excluding amounts included in net interest on the net defined benefit liability), are recognised immediately in the balance sheet with a corresponding debit or credit to profit or loss through OCI in the period in which they occur. Re measurements are not reclassified to profit or loss in subsequent periods.

1.3.8 Foreign Exchange Transactions

These financial statements are presented in Indian Rupees (INR), which is the Company's functional currency.





Notes to Consolidated Financial Statements

Transactions in foreign currency are recorded on initial recognition at the spot rate prevailing at the time of the transaction.

At the end of each reporting period

- Monetary items (Assets and Liabilities) denominated in foreign currencies are retranslated at the rates prevailing at that date.
- Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing at the date when the fair value was determined.
- Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated Exchange differences on monetary items are recognized in profit or loss in the period in which they arise.

1.3.9 Fair Value Measurement:

The Company measures financial instruments at fair value at each balance sheet date. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

In the principal market for the asset or liability, or
 In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible by the Company. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 Quoted (unadjusted) market prices in active markets for identical assets or liabilities
- Level 2 Valuation techniques for which the lowest level input that is significant





Notes to Consolidated Financial Statements

to the fair value measurement is directly or indirectly observable

• Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

For assets and liabilities that are recognised in the financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by reassessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

For the purpose of fair value disclosures, the Company has determined classes of assets & liabilities on the basis of the nature, characteristics and the risks of the asset or liability and the level of the fair value hierarchy as explained above.

1.3.10 Financial Instrument

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

a) Recognition

The company recognizes financial assets and financial liabilities when it becomes party to the contractual provisions of the instrument

b) Measurement

i) Financial assets

A financial asset is measured at

- amortised cost or
- fair value either through other compressive income or through profit or loss
- ii) Financial liability

A financial liabilities is measured at

- amortised cost using the effective interest method or
- fair value through profit or loss.

iii) Initial recognition and measurement:

All financial assets and liabilities are recognized at fair value at initial recognition, plus or minus, any transaction cost that are directly attributable to the acquisition or issue of financial assets and financial liabilities that are not at fair value through profit or loss.





Notes to Consolidated Financial Statements

iv) Subsequent measurement

Financial assets as subsequent measured at amortised cost or fair value through other comprehensive income (FVOCI) or fair value through profit or loss (FVTPL) as the case may be.

Financial liabilities as subsequent measured at amortised cost or fair value through profit or loss.

c) Financial assets

i) Trade Receivables:

Trade receivables are the contractual right to receive cash or other financial assets and recognized initially at fair value. Subsequently measured at amortised cost (Initial fair value less expected credit loss). Expected credit loss is the difference between all contractual cash flows that are due to the company and all that the company expects to receive (i.e. all cash shortfall), discounted at the effective interest rate.

ii) Equity investments -Investment in Subsidiary, associates & Joint venture Investment in Subsidiary, associates & Joint venture is carried at cost as per Ind AS27

All other equity investments in scope of Ind AS 109 are measured at fair value. Equity instruments which are held for trading and contingent consideration recognised by an acquirer in a business combination to which Ind AS103 applies are classified as at FVTPL. For all other equity instruments, the company may make an irrevocable election to present in other comprehensive income subsequent changes in the fair value. The Company makes such election on an instrument by- instrument basis. The classification is made on initial recognition and is irrevocable.

If the Company decides to classify an equity instrument as at Fair value to other comprehensive income (FVTOCI), then all fair value changes on the instrument, excluding dividends, are recognized in the OCI. There is no recycling of the amounts from OCI to P&L, even on sale of investment. However, the company may transfer the cumulative gain or loss within equity.

Equity instruments included within the FVTPL category are measured at fair value with all changes recognized in the P&L.

d) Cash and cash Equivalents:

Cash and cash equivalent in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.



Notes to Consolidated Financial Statements

e) Impairment of Financial Assets:

The Company recognizes loss allowances using theexpected credit loss (ECL) model for the financial sets which are not fair valued through profit or loss. Loss allowance for trade receivables with no significant financing component is measured at an amount equal tolifetime ECL. For all other financial assets, expected credit losses are measured at an amount equal to the 12-month ECL, unless there has been a significant increase incredit risk from initial recognition in which case those are measured at lifetime ECL. The amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognised is recognized as an impairment gain or loss in profit or loss.

f) Financial liabilities

i) Trade payables:

Trade payables represent liabilities for goods and services provided to the Company prior to the end of financial year and which are unpaid. Trade payables are presented as current liabilities unless payment is not due within 12 months after the reporting period or not paid/payable within operating cycle. They are recognised initially at their fair value and subsequently measured at amortised cost using the effective interest method.

ii) Borrowings:

Borrowings are initially recognised at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortised cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognised in profit or loss over the period of the borrowings using the effective interest method. Fees paid on the establishment of loan facilities are recognised as transaction costs of the loan.

Borrowings are classified as current liabilities unless the Company has an unconditional right to defer settlement of the liability for at least 12 months after the reporting period. Where there is a breach of a material provision of a long-term loan arrangement on or before the end of the reporting period with the effect that the liability becomes payable on demand on the reporting date, the company does not classify the liability as current, if the lender agreed, after the reporting period and before the approval of the financial statements for issue, not to demand payment as a consequence of the breach.

iii) Equity Instruments:

An equity instrument is any contract that evidences a residual interest in the assets of company after deducting all of its liabilities. Equity instruments are recognised at the proceeds received, net of direct issue costs.





CIN: U85110DL2008PLC174706

Notes to Consolidated Financial Statements

g) Derecognition of financial instrument:

The company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire or it transfers the financial asset and the transfer qualifies for derecognition under Ind AS 109. A financial liability (or a part of a financial liability) is derecognized from the company's balance sheet when the obligation specified in the contract is discharged or cancelled or expires.

h) Offsetting of financial instruments:

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously

i) Financial guarantee

Financial guarantee contracts issued by the Company are those contracts that require a payment to be made to reimburse the holder for a loss it incurs because the specified debtor fails to make a payment when due in accordance with the terms of a debt instrument. Financial guarantee contracts are recognised initially as a liability at fair value, adjusted for transaction costs that are directly attributable to the issuance of the guarantee. Subsequently, the liability is measured at the higher of the amount of loss allowance determined asper impairment requirements of IND AS 109 and the amount recognised less cumulative amortization.

1.3.11 Operating cycle:

Based on the nature of products / activities of the Company and the normal time between acquisition of assets and their realisation in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.

1.3.12 Earning Per Share

The Earning per share is computed in accordance with the IND AS 33. Basic earnings per share are calculated by dividing the net profit or loss for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.





Notes to Consolidated Financial Statements

1.3.13 Provisions, Contingent Liabilities and Contingent Assets

I. A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The Company does not recognize a contingent liability but discloses its existence in the financial statements. Contingent liabilities, if material, are disclosed by way of notes and contingent assets, if any, is disclosed in the notes to financial statements.

Contingent liabilities, which according to the management are not expected to materialize are not recognized in the financial statements are disclosed in the notes to the accounts. Contingent assets are neither recognized nor disclosed in financial statements.

II. A provision is recognized, when Company has a present obligation (legal or constructive) as a result of past events and it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, in respect of which a reliable estimate can be made for the amount of obligation. The expense relating to the provision is presented in the profit and loss net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pretax rate that reflects, when appropriate, the risks.

1.3.14 Segment Reporting

The company is mainly into the business of rendering hospital services. Other services like sale of medicine etc are ancillary to the main services and thus the only business segment, in terms of IND AS 108 and therefore noseparate reporting under 'Segment Reporting' is required

1.3.15 Cash flows

Cash flows are reported using the indirect method, where by profit before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The Cash flows from operating, investing and financing activities of the company are segregated





Notes to Consolidated Financial Statements

1.3.16 Impairment of Assets

The Company assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) fair value less costs of disposal and its value in use. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for publicly traded companies or other available fair value indicators.

Impairment losses of continuing operations, including impairment on inventories, are recognised in the statement of profit and loss, except for properties previously revalued with the revaluation surplus taken to Other Comprehensive Income (OCI). For such properties, the impairment is recognised in OCI up to the amount of any previous revaluation surplus.

For assets other than goodwill, an assessment is made at each reporting date to determine whether there is an indication that previously recognised impairment losses no longer exist or have decreased. If such indication exists, the Company estimates the asset's or CGU's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. Such reversal is recognised in the statement of profit or loss unless the asset is carried at a revalued amount, in which case, the reversal is treated as a revaluation increase.

Goodwill is tested for impairment as at each Balance Sheet date and when circumstances indicate that the carrying value may be impaired.

Impairment is determined for goodwill by assessing the recoverable amount of each CGU (or group of CGUs) to which the goodwill relates. When the recoverable amount of the CGU is less than its carrying amount, an impairment loss is recognised. Impairment losses relating to goodwill cannot be reversed in future periods.

Notes to Consolidated Financial Statements

Intangible assets with indefinite useful lives are tested for impairment annually as at each Balance sheet date at the CGU level, as appropriate, and when circumstances indicate that the carrying value may be impaired.

When an impairment loss subsequently reverses, the carrying amount of the asset (or a cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or Loss.

1.3.17 Current and non-current assets and liabilities

All financials assets and liabilities maturing with-in the time period of operating cycle which at present is 1 year are considered current assets or liabilities. All assets and liabilities, not being current are considered noncurrent assets or liabilities.

1.3.18 Expenditure during construction period:

Assets in the course of construction are capitalized in the assets and treated as capital work in progress and upon commissioning of project the assets are capitalised and transferred to appropriate category of PPE. At the point when an asset is operating at management's intended use, the cost of construction is transferred to appropriate category of PPE.





(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)
CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

2. Property, Plant & Equipment

2. 1 Toperty, 1 lant & Equipment	Lease Hold	Free Hold		Plant &	Furniture &	Office		
Particulars	Land*	Land	Buildings	Machinery	Fittings	Equipments	Vehicles	Total
Cost as at 1st April, 2021	180.31	-	1,782.30	868.46	45.15	314.02	60.53	3,250.76
Additions	15	-	27.08	23.84	4.54	25.48	16.45	97.39
Additions through business combination		25.31	228.09	182.92	30.43	142.89	7.54	617.17
Disposals	-			170		-	-	-
Cost as at 31st March, 2022 (A)	180.31	25.31	2,037.46	1,075.22	80.12	482.39	84.52	3,965.32
Cost as at 1st April, 2022	180.31	25.31	2,037.46	1,075.22	80.12	482.39	84.52	3,965.32
Additions	-	-	48.32	149.72	11.90	18.50	0.84	229.28
Additions through business combination	-	-	-	-	8	-	-	3
Disposals	-	-	-	-	8	-	-	9
Cost as at 31st March, 2023 (C)	180.31	25.31	2,085.78	1,224.93	92.02	500.89	85.35	4,194.60
		2						,
Accumulated Depreciation								
Accumulated Depreciation as at 1st April, 2021	5.62	-	205.48	395.08	16.68	164.76	34.76	822.39
Depreciation for the year	2.17	-	100.34	99.15	8.99	37.32	10.67	258.64
Depreciation on business combinations			49.54	124.79	22.99	101.86	7.31	306.49
Disposals	-		-		-	(17)	-	
Accumulated Depreciation as at 31st March, 2022 (B)	7.79	-	355.36	619.03	48.66	303.94	52.74	1,387.51
			257.24	×10.00	10.66	202.04	52.74	1 207 51
Accumulated Depreciation as at 1st April, 2022	7.79	7	355.36	619.03	48.66	303.94	52.74	1,387.51
Depreciation for the year	2.17	-	82.21	105.98	9.57	44.21	9.87	254.00
Depreciation on business combinations		-	9.70	7	-	-	-	-
Disposals			125.55	-		740.14	(2.(1	1 (41 51
Accumulated Depreciation as at 31st March, 2023 (D)	9.96		437.57	725.00	58.23	348.14	62.61	1,641.51
Net Carrying Amount								
As at 31st March, 2022 (A-B)	172.51	25.31	1,682,10	456.19	31.46	178.45	31.78	2,577.81
As at 31st March, 2023 (C-D)	170,34	25.31	1,648.21	499.93	33.80	152.75	22.75	2,553.09
*Leasehold Land is for a perpetual lease period of 90 Years								





(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

3. Intangible Assets		
Particulars	Computer Software	Total
Cost as at 1st April, 2021		
Additions	·-	-
Additions through business combination	1.12	1.12
Disposals	1.12	1.12
Cost as at 31st March, 2022 (A)	1.12	1.12
Cost as at 1st April, 2022	1.12	1.12
Additions	-	
Additions through business combination	-	-
Disposals		-
Cost as at 31st March, 2023 (C)	1.12	1.12
Accumulated Depreciation		
Accumulated Depreciation as at 1st April, 2021		
Depreciation on business combination	1.05	1.05
Disposals	1.03	1.05
Accumulated Depreciation as at 31st March, 2022 (B)	1.05	1.05
		8
Accumulated Depreciation as at 1st April, 2022	1.05	1.05
Depreciation	0.07	0.07
Disposals	-	-
Accumulated Depreciation as at 31st March, 2023 (D)	1.12	1.12
Net Carrying Amount		
As at 31st March, 2022 (A-B)	0.07	
As at 31st March, 2023 (C-D)	0.07	0.07
	-	-





(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All	amounts	in	million,	unless	otherwise stated)
---	-----	---------	----	----------	--------	------------------	---

Note No.	Particulars	As at March 31, 2023	As at March 31, 2022
4	Other Financial Assets		
	Security Deposits- with Government Departments	8.49	9.91
	Bank Deposits with more than 12 months maturity- Pledged with bank for bank guarantees	11.07	12.34
	Total	19.56	22.25
5	Other Non Current Assets		
	Capital Advances	9.41	40.55
	Advance Income Tax and TDS (Net of Provisions)	-	17.90
	Total	9.41	58.45
6	Inventories		
	(Valued at lower of cost or net realisable value)		5
	Consumable Pharmacy	42.23	41.67
	Consumables Stores	18.47	10.28
	Total	60.70	51.95
7	Trade Receivables		
	(a) Trade Receivables considered good - Secured		
	Others		-
	(b) Trade Receivables considered good - Unsecured		
	Related parties	-	-
	Others	1,148.21	912.22
		1,148.21	912.22
	Less: - Provision for Credit risk	71.76	56.84
	Net Trade Receivables	1,076.44	855.38
			" g
	(c) Trade Receivables which have significant increase in Credit Risk-Doubtful	-	
	Total	1,076.44	855.38

Trade receivables are unsecured and are derived from revenue earned from providing medical, healtcare and other ancillary services. No interest is charged on the outstanding balance, regardless of the age of the balance. The group applies Expected Credit Loss (ECL) model for measurement and recognition of impairment loss towards expected risk of delays and default in collection.

The group has used a practical expedient by computing the expected credit loss allowance based on recovery pattern of receivables in the past. Management makes specific provision in cases where there are known specific risks of customer default in making repayments. The provision matrix takes into account historical credit loss experience and adjusted for forward-looking information.



(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

Trade Receivable aging schedule As at 31st March, 2023

Particulars	Outstanding for following periods						
	_	Less than 6 months	6 Months-1 year	1-2 years	2-3 years	More than 3 years	Total
a) Undisputed Trade receivables- Considered Good		882.85	220.04	45.30	0.01	-	1,148.21
b) Undisputed Trade receivables- Considered Doubtful		-		-	-	-	-
c) Undisputed Trade receivables- Credit Impaired		-		-	-	-	-
d) Disputed Trade receivables- Considered Good		-		1 2	-	-	
e) Disputed Trade receivables- Considered Doubtful	1			-:	-		
f) Disputed Trade receivables- Credit Impaired				-	-	: ×:	

As at 31st March, 2022

Particulars		Outstanding for following periods					
	Less than 6 months	6 Months-1 year	1-2 years	2-3 years	More than 3 years	Total	
a) Undisputed Trade receivables- Considered Good	680.04	230.97	1.22	(-1)		912.22	
b) Undisputed Trade receivables- Considered Doubtful	-	(=)	-	-	-	-	
c) Undisputed Trade receivables- Credit Impaired	-	(2)	-	120	2	100	
d) Disputed Trade receivables- Considered Good	2	(20)	-	120		-	
e) Disputed Trade receivables- Considered Doubtful	¥		-	_	-	-	
f) Disputed Trade receivables- Credit Impaired	8		-	-		17.	





(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

Note No.	Particulars	As at March 31, 2023	As at March 31, 2022
8	Cash and Cash Equivalants		
	Balance with banks in current accounts	354.24	111.52
	UPI & Other Amount Recoverable	2.56	2.12
	Cash in hand	15.45	2.93
	Bank Deposits with maturing with in 3 months- pledged with banks	2.08	0.51
	Total	374.32	117.07
9	Bank balances other than cash and cash equivalents		
	Bank Deposits & Interest accured on Bank deposit	10.11	3.74
	Total	10.11	3.74
10	Current Tax Assets		
	TDS & Advance income tax (net of provision for income tax)	111.78	30.23
	Total	111.78	30.23
11	Other Current Assets		
	Staff Imprest and Advances	1.62	4.27
	Other amount recoverable	59.23	8.67
	Unamortised capital issue expenses	63.04	21.41
	Security Deposit-others	5.43	1.28
	Total	129.31	35.63

^{*} The Parent Company has incurred expenses towards various services received in connection with the proposed issue of fresh equity shares by the Company and the sale of equity shares by the existing shareholders by the way of Offer for Sale.





(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

12 Share Capital	As at March 31, 2023	As at March 31, 2022
Authorised		
115,000,000 (Previous Year 115,000,000 Equity shares) of Rs. 10/- each	1,150.00	1,150.00
Total	1,150.00	1,150.00
Equity share capital		,
Issued, Subscribed & Paid up		
65,516,900 (Previous Year 65,516,900 Equity shares) of Rs. 10/- each	655.17	655.17
Issued, Subscribed & Not Paid up		
NIL		
Total	655.17	655.17
2.1 Reconciliation of number of shares outstanding at the beginning and at the Equity Shares	he end of the reporting peri	od
Number of Shares outstanding at the beginning of the year	65,516,900	16,379,225
Number of Shares issued during the year in cash	-	
Number of Shares issued during the year other than in cash	-	49,137,675
Number of Shares brought back during the year	-	,137,073
Shares outstanding at the end of the year	65,516,900	65,516,900

12.2 Terms / rights attached to Equity shares

The Company has only one class of equity shares having a par value of Rs.10 per share. Each holder of equity shares is entitled to one vote per share.

In the event of the liquidation of the Company, the holder of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

12.3 Equity Shares in the company held by each shareholder holding more than 5 percent shares specifying the number of shares held

Name of Shareholder	As at Mar	As at March 31, 2022		
	No. of equity shares held	% of holding	No. of equity shares held	% of holding
Dr. Ajay Kumar Tyagi	27,021,600	41.24%	27,021,600	41.24%
Dr. Kapil Kumar	12,164,400	18.57%	12,164,400	18.57%
Dr. Manju Tyagi	11,524,200	17.59%	11,524,200	17.59%
Dr. Neena Tyagi	7,019,600	10.71%	7,019,600	10.71%
Vimla Tyagi	3,743,000	5.71%	3,743,000	5.71%

12.4 Equity shares reserved for issue under options and contracts / commitments for the sale of shares / disinvestments, including terms and amounts NIL





(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

12.5 Aggregate number and class of equity shares allotted as fully paid up pursuant to contract without payment being received in cash, allotment by way of bonus shares or shares bought back

Particulars	2022-23	2021-22	2020-21	2019-20	2018-19
Company has allotted 49.14 million equity shares of Rs. 10 each, valued at Rs. 491.38 million on to existing shareholders by way of capitalisation of Share premium and accumulated Profit & Loss during FY 2021-22	<u>-</u>	49,137,675	-	-	

12.6 The company does not have any holding company or ultimate holding company.

12.7 Shareholding of Promoters

S. No. Name of Shareholder

As at March 31, 2023

As at March 31, 2022

		No. of equity shares held	% of total shares	% Change during Year	No. of equity shares held	% of total shares	% Change during Year
1	Dr. Ajay Kumar Tyagi						
	Opening Balance	27,021,600	41.24%		6,755,400	41.24%	
	Acquired During the year *	-			20,266,200	30.93%	
	Closing Balance	27,021,600	41.24%	1.00	27,021,600	41.24%	300.00%
2	Dr. Kapil Kumar						
	Opening Balance	12,164,400	18.57%		3,041,100	18.57%	
	Acquired During the year *	-	-		9,123,300	13.93%	
	Closing Balance	12,164,400	18.57%	-	12,164,400	18.57%	300.00%

* Acquired by the way of Bonus shares issued by the Company





(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

13 Other Equity

Particulars	Securities Premium	Retained Earnings	Other Comprehensive Income	Equity attributable to shareholders of the company
Balance as at 1st April, 2021	176.	50 384.13	0.02	560.76
Surplus in the statement of profit and loss transferred during the year		441.62	-	441.62
Issue of Bonus Shares	(176.	50) (314.77)	-	(491.38)
Remeasurement of defined benefit liability (net of tax)	1.0	-	2.67	2.67
Balance as at 31st March, 2022	-	510.98	2.70	513.68

Particulars	Securities Premium	Retained Earnings	Other Comprehensive Income	Equity attributable to shareholders of the company	
Balance as at 1st April, 2022		- 510.98	2.70	513.68	
Surplus in the statement of profit and loss transferred during the year Issue of Bonus Shares		- 657.68	-	657.68	
			=	-	
Remeasurement of defined benefit liability (net of tax)		±.	3.11	3.11	
Balance as at 31st March, 2023		- 1,168.66	5.81	1,174.47	

Securities Premium

Securities premium is used to record the premium received on issue of shares. It is utilised in accordance with the provisions of the Companies Act, 2013.

Retained Earnings

The amount that can be distributed by the company as dividends to pay its equity and preference (if any) shareholders.

Other Comprehensive Income

Remeasurement of defined benefit plans comprise of acturial gains and losses.





(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

Note No.	Particulars	As at March 31, 2023	As at March 31, 2022
14	Borrowings		
	Secured		
	Term loans (Indian currency)		
	From banks	2,373.59	2,325.60
	From financial institutions	82.83	78.17
	Less: Current Maturities[refer note no. 17]	463.26	348.91
	Less. Current Maturities refer note no. 17	1,993.16	2,054.86
	Loan for Vehicles against hypothecation - Banks	12.78	18.96
	Unsecured		
	From banks	-	-1
	From financial institutions	· <u>-</u> .	=
	Total	2,005.94	2,073.82
	For terms and conditions, security and repayments please refer note no 35		
15	Provisions		
	Provision for employee benefit	12.99	9.78
	Total	12.99	9.78
16	Deferred Tax Asset-Net		
	Deferred tax liabilities		
	On account of Depreciation	88.54	91.73
	On account of Others	0.52	1.29
	Sub Total (A)	89.05	93.01
	Deferred tax Assets		
	On account of Losses and Tax disallowances	144.79	112.33
	On account of Others	22.18	19.30
	MAT credit entitlement	4.87	15.90
	Sub Total (B)	171.85	147.54
	Deferred Tax Asset-Net (A-B)	(82.79)	(54.53)
	For movement of deferred Tax, refer Note 16.1	3 ·	
	v ten manuscom modernica de construire de co		





YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED (Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

Note No. 16.1

Deferred Tax Assets/Deferred Tax Liabilities

As on 31st March, 2022

Particulars	Opening balance	Recognised in Profit or loss	Acquired during the year	Other Comprehensive Income	Closing balance
Deferred tax assets in relation to:				CO. 102-17-29-18-18	
MAT Credit	33.92	(18.02)	-		15.90
Provision for employee benefits	0.13	3.80	-	(1.10)	2,83
Business loss & Tax disallowance benefit carried forward and others	2.87	0.11	109.35		112.33
On IND AS Adjustments	4.76	11.71	-		16.47
Deferred Tax Assets Total	41.68	(2.39)	109.35	(1.10)	147.54
Deferred tax liabilities on account of					
Due to depreciation	78.57	7.29	5.87	-	91.73
Others	1.62	(0.34)	-	-	1.29
Deferred Tax Liabilities Total	80.19	6,95	5.87		93.01
Deferred Tax Assets/(Liability)	(38.52)	(9.34)	103.48	(1.10)	54.53

As on 31st March, 2023

Particulars	Opening balance	Recognised in Profit or loss	Acquired during the year	Other Comprehensive Income	Closing balance
Deferred tax assets in relation to:					
MAT Credit	15.90	(11.03)			4.87
Provision for employee benefits	2.83	1.62		(0.90)	3.55
Business loss & Tax disallowance benefit carried forward and others	112.33	32.46	-	-	144.79
On IND AS Adjustments	16.47	2.16	-		18.63
Deferred Tax Assets Total	147.54	25.20	-	(0.90)	171.85
Deferred tax liabilities on account of					
Due to depreciation	91.73	(3.19)	-		88.54
Others	1.29	(0.77)	-		0.52
Deferred Tax Liabilities Total	93.01	(3.96)	-	-	89.05
Deferred Tax Assets/(Liability)	54.53	29.16	-	(0.90)	82.79





(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

Note		As at March 31,	As at March 31,
No.	Particulars	2023	2022
17	Borrowings*		
	Secured		
	Working Capital from Banks	162.94	100.46
	Current maturities of Long Term Borrowings		
	From banks	431.75	322.44
	From financial institutions	31.51	26.47
	Loan for Vehicles against hypothecation- Banks	. 5.61	7.05
	Unsecured		
	From banks	2	-
	From financial institutions		
	From Directors	2	51.64
		631.82	508.06
	*For terms and conditions, security and repayments ple	ase refer note no 35	
18	Trade payables (refer note no. 33)		
	(a) Due to Micro and small enterprises	15.08	22.81
	(b) Due to others	153.69	181.31

Trade Payables Ageing Schedule

As at 31st March, 2023

Total

Particulars	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years	Total
a) MSME	15.08	-		-	15.08
b) Others	153.69		14	0=	153.69
c) Disputed dues- MSME	18 1 4 0	100		-	·
d) Disputed dues- Others	F	(2)	(4)	(-)-
Total	168.78	-	-	25	168.78

204.12

168.78

As at 31st March, 2022

Particulars	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years	Total
77 Periodical Control	22.81	I Z I Cars	2010110		22.81
a) MSME			0.50		181.31
b) Others	181.31	-		-	181.31
c) Disputed dues- MSME	-	-	-	-	-
d) Disputed dues- Others	-	-	-		-
Total	204.12	-	-	=	204.12





(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

		As at March 31, A	As at March 31,
Note No.	Particulars	2023	2022
19	Other Financial Liabilities		
	Liability for land	-	-
	Interest accrued but not due	1.13	0.73
	Expenses Payable	141.27	144.63
	Total	142.40	145.36
20	Other Current Liabilities	0.010	05.00
	Statutory Dues	26.46	25.33
	Other Liabilities	Ξ.,	0.56
	Advances from customer	4.69	6.39
	Total	31.15	32.28
21	Provisions		
	Provision for employee benefit	0.59	0.05
	Provision for taxation - Net of Advance Tax	-	62.06
	Total	0.59	62.10





(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

Note No.	Particulars	Year ended 31-March-2023	Year ended 31-March-2022
22	Revenue from operations	OI MAICH 2023	CA ITAMI CII-AUAA
	*		
	Income from medical and healthcare services*	5,202.93	4,009.37
	Total	5,202.93	4,009.37
	*Refer Note 34		
23	Other income		
	Interest income on bank deposits	1.41	1.02
	Interest on income tax refund	2.86	5.38
	Other incomes- Sale of Food & Beverages	21.96	9.34
	Rental Income from telecom towers	0.89	0.75
	Interest income - INDAS	0.01	0.00
	Rental Income from Ambulance Total	0.94	-
	Total	28.07	16.49
24	Cost of Material Consumed		
	Medicines consumed		
	Opening balance	41.67	20.67
	Purchase	444.21	521.20
	Less: closing stock	(42.23)	(41.67
	Material Consumed-A	443.66	500.19
	Consumable stores		
	Opening balance	10.28	13.23
	Purchase	493.88	310.14
	Less: closing stock	(18.47)	(10.28
	Stores Consumed-B	485.69	313.09
	TOTAL COST OF MATERIAL CONSUMED A+B	929.35	813.28
25	Employee benefits expense		
	Salaries, wages and other benefits	848.72	737.77
	Director's Remuneration	60.00	55.00
	Key men insurance	1,34	1.48
	Staff welfare expenses	9.24	10.43
	Total	919.30	804.68
	×		
26	Finance cost		Haffesta (Tarris
	Interest on secured loans	203.80	190.46
	Interest expense on Lease Liability	2.21	2.98
	Interest on unsecured loans	-	0.57
	Interest on others	0.13	13.47
	Interest on Others-MSME	0.13	0.18
	Interest on Statutory Dues	7.61	7.20
	Total	213.87	214.86
27	Depreciation and amortization expenses		
- /	Depreciation on Property, Plant & Equipment and Intangible Assets	254.07	257.93
	Depreciation on Leased Assets	21.00	20.76
	Total	ARROW	And Fall
	apal Asso	275.07	278.68
	() ()		

Annexure VI Notes to Restated Consolidated Financial Information

Note		Year ended	Year ended
No.	Particulars	31-March-2023	31-March-2022
20	Other avacues		
28	Other expenses Specialist Charges	020.01	510.00
	Lab Expenses	930.91	510.22
	Power, Fuel & Utilities	50.10	37.17
	Advertisement & Marketing	137.11	121.88
	Vehicle running & maintenance	43.99	10.96
	Repair & maintenance	27.69 179.63	25.70 87.50
	Discount allowed	426.17	260.55
	Provision for Expected credit loss	14.93	36.60
	Bank & Finance Charge	13.96	11.61
	Filling Fees	0.05	8.61
	Legal & Professional Charges	12.39	1.95
	Canteen & food	43.57	50.77
	CSR Expenses		
	0.0 Mill 0000000 • 11000000000	6.70	3.00
	Conveyance & travel	27.57	12.89
	Director's Sitting Fees	0.93	0.42
	Rent Printing & stationers	19.39	18.50
	Printing & stationery	2.51	8.24
	Office expenses	53.87	49.94
	Communication Exp	3.85	5.08
	Insurance expenses Auditor's remuneration	3.45	0.72
	Control of the conformation of the control of the c	1.10	0.72
	- For Audit fees	1.12	0.73
	Other Miscellaneous Expenses	16.75	20.22
	Total	2,016.63	1,283.29
29	Earning per Share		
29	Profit for the year attributable to owners of the company	660.79	444.30
		000.17	111.50
	Shares		
	Weighted Average number of equity shares at the beginning of the year	65,516,900	65,516,900
Add	Weighted Average number of equity shares issued during the year	-	-
	Weighted Average number of equity shares at the end of the year	65,516,900	65,516,900
Add/	Bonus shares issued subsequent to period end considered for calculation of Earning per		
(Less)	share for relevant periods.	-	-
4.4.47		65,516,900	65,516,900
Add/ (Less)	Items having dilutive impact on equity shares		-
	Weighted Average number of equity shares (without bonus shares) at the end of the year-		
	Diluted EPS	65,516,900	65,516,900
	Earnings Per Share- Rs	10.09	6.78
	Diluted Earnings Per Share- Rs	10.09	6.78
	Weighted Average number of equity shares (with bonus shares) at the end of the year-		
	Diluted EPS	65,516,900	65,516,900
	Earnings Per Share- Rs	10.09	6.78
	Diluted Earnings Per Share- Rs	10.09	6.78
		/	grauma



(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)
CIN:U85110DL2008PLC174706
Notes to Consolidated Financial Information
(All amounts in million, unless otherwise stated)

30 Right of Use Assets

A. Transition to Ind AS 116 "Leases"

A new lease standard i.e., Ind AS 116 has been notified to be effective w.e.f. 1 April 2019 which provide guidelines for the accounting of the lease contracts entered in the capacity of a lessee and a lessor. For the purpose of preparation of Restated Standalone Financial Information, the management has evaluated the impact of change in accounting policies on adoption of Ind AS 116 for the year ended 31 March 2019. Hence in these Restated Standalone Financial Information, Ind AS 116 has been adopted with effect from April 1, 2018 following modified retrospective method (i.e. on 1 April 2018 the company has measured the lease liability at the present value of the remaining lease payments, discounted using the lessee's incremental borrowing rate and a right-of-use assets are measured at their carrying amount as if Ind AS 116 had been applied since the commencement date, discounted using the lessee's incremental borrowing rate at the date of initial application).

Ind AS 116 supersedes Ind AS 17 Leases including its appendices (Appendix C of Ind AS 17 Determining whether an Arrangement contains a Lease, Appendix A of Ind AS 17 Operating Leases- Incentives and Appendix B of Ind AS 17 Evaluating the Substance of Transactions Involving the Legal Form of a Lease). The standard sets out the principles for the recognition, measurement, presentation and disclosure of leases and requires lessees to recognise most leases on the balance sheet. Following are the changes in the carrying values of right of use assets for the year ended March 31, 2023 & 31 March 2022:

The company has elected not to apply the requirements of Ind AS 116 "Leases" to short-term leases of all assets that have a lease term of 12 months or less and leases for which the underlying asset is of low value. The lease payments associated with these leases are recognized as an expense on a straight-line basis over the lease term except inflation adjustment.

B. Following are the changes in the carrying values of right of use assets

Following are the changes Particulars	Category of ROU Assets- Medical Equiptments	Category of ROU Assets- Office	Total
Gross Block			
Balance as at April 1, 2021	123.57	12 m	123.57
Additions	0 - 0	1.24	1.24
Deletion	9 . €9	: - :	-
Balance as at March 31, 2022A	123.57	1.24	124.81
Additions	~	12	
Deletion	-	14	-
Balance as at March 31, 2023B	123.57	1.24	124.81
Accumulated Depreciation			
Accmulated Depreciation as at April 1, 2021	47.94	1 ±	47.94
Depreciation charge for the year	20.58	0.17	20.76
Disposals			-
Accmulated Depreciation as at March 31, 2022C	68.52	0.17	68.69
Depreciation charge for the year	20.58	0.41	21.00
Disposals	(F)	¥	(4)
Accmulated Depreciation as at March 31, 2023 D	89.11	0.59	89.69
Net Carrying amounts			
As at March 31, 2022 (A-C)	55.04	1.07	56.12
As at March 31, 2023 (B-D)	34.46	0.66	35.12

The aggregate depreciation expense on ROU assets is included under depreciation and amortization expense in the statement of Profit and Loss.

C. The following is the rental expense recorded for short-term leases, variable leases and low value assets

	For the	For the	
Particulars	year ended	year ended	
	March 31, 2023	31 March 2022	
Short Term Lease	19.39	18.50	





(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

D. Following is the movement in lease liabilities for the year ended March 31, 2023

Particulars	Lease liabilities
Balance as at 1 April 2021	73.02
Additions	1.24
Finance cost	3.02
Payment of lease liabilities	
Balance as at 31 March 2022	21.43
Non-current lease liabilities	55.85
Current lease liabilities	36.74 19.12
	19.12
Balance as at 1 April 2022	55,85
Additions	-
Finance cost	2.21
Payment of lease liabilities	21.70
Balance as at March 31, 2023	36.36
Non-current lease liabilities	
Current lease liabilities	15.91
	20.45

E. The following is the cash outflow on leases during the years:

Particulars	For the year ended March 31, 2023	For the year ended 31 March 2022
Payment of lease liabilities	21.70	21.43
Short-term lease expense	19.39	18.50
Total cash outflow on leases	41.09	39.93

F. The table below provides details regarding the contractual maturities of lease liabilities as at year-end on an undiscounted basis:

Description of the second of t	For the	For the
Particulars	year ended March 31, 2023	year ended 31 March 2022
Less than 1 year	28.37	28.80
1 to 5 years More than 5 years	16.69	37.95

The company does not face a significant liquidity risk with regard to its lease liabilities as the current assets are sufficient to meet the obligations related to lease liabilities as and when they fall due.





(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

Note 31 (i): Fair Value Measurement Categories of financial instruments

Financial assets	As at March 31, 2023	As at March 31, 2022
Measured at amortised cost		
(i) Trade receivables	1,076.44	855.38
(ii) Cash and Bank balance	374.32	117.07
(iii) Other Bank Balances	10.11	3.74
(iv) Other financial assets-non current	19.56	22.25
	1,480.45	998.44
Measured at Fair value		
Investment other than investment in subsidiaries	ž.	-
Financial liabilities	As at March 31,	As at March 31,
Timanetai nabinties	2023	2022
Measured at amortised cost		
(i) Borrowings	2,637.76	2,581.88
(ii) Other financial liabilities	142.40	145.36
(iii) Lease Liabilities	36.36	55.85
(iv) Trade and other payables	168.78	204.12
Total	2,985.29	2,987.22

(i) Fair Value Hierarchy

Fair value measurements

Particulars		Fair value as at		
		As at March 31, 2023	As at March 31, 2022	
Financial assets		-	-	
Financial Liabilities		-	-	

The fair values of current debtors, cash & bank balances, loan to related party, security deposit to government department, current creditors and current borrowings and other financial liability are assumed to approximate their carrying amounts due to the short-term maturities of these assets and liabilities.

	Carryin	ig value
Particulars	As at March 31, 2023	As at March 31, 2022
i) Financial assets - Current		
Trade receivables	1,076.44	855.38
Cash and cash equivalents	15.45	2.93
Bank Balances	354.24	113.64
Other Bank balances	10.11	3.74
ii) Financial liabilities - Current		
Trade payables	168.78	204.12
Borrowing	631.82	508.06
Lease Liabilities	20.45	19.12
Other financial liabilities	142.40	145.36

(ii) Valuation techniques used to determine Fair value

The Company maintains policies and procedures to value financial assets or financial liabilities using the best and most relevant data available. The fair values of the Thangal assets and liabilities are included at the amount that would be received to sell an asset or paid to transfer a hability in an orderly transaction between market participants at the measurement date.

(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

Note 31(ii): FINANCIAL RISK MANAGEMENT

The Company's principal financial liabilities other than derivatives comprise loans and borrowings trade and other payables. The main purpose of these financial liabilities is to finance the Company's operations. The Company's principal financial assets include Lease assets, loans trade and other receivables and cash and cash equivalents that are derived directly from its operations.

The Company's financial risk management is an integral part of how to plan and execute its business strategies. The Company is exposed to market risk credit risk and liquidity risk. The company's focus is to foresee the unpredictability of financial markets and seek to minimize potential adverse effects on its financial performance.

The Company's principal financial liabilities comprise borrowings trade and other payables. The main purpose of these financial liabilities is to manage finances for the Company's operations. The Company principal financial asset includes loan trade and other receivables and cash and short-term deposits that arise directly from its operations.

The Company's activities are exposed to market risk, credit risk and liquidity risk.

I. Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market prices comprise three types of risk: currency rate risk interest rate risk and other price risks such as equity price risk and commodity price risk. Financial instruments affected by market risk include loans and borrowings deposits investments and derivative financial instruments.

The sensitivity of the relevant profit or loss item is the effect of the assumed changes in respective market risks.

(a) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. In order to optimize the Company's position with regard to interest income and interest expenses and to manage the interest rate risk treasury performs a comprehensive corporate interest rate risk management by balancing the proportion of the fixed rate and floating rate financial instruments in its total portfolio.

(i) The exposure of group borrowings to interest rate changes at the end of reporting period are as follows (except for lease liabilities)

Particulars	As at March 31, 2023	As at March 31 2022
Variable rate borrowings	2,628.62	2,503.72
Fixed rate borrowings	12.43	26.52
Total borrowings	2,641.06	2,530.24

(ii) As at the end of reporting period the company had the following variable rate borrowings and interest rate swap contracts outstanding:

	As at March 31, 2023			As at March 31 2022		
Particulars	Weighted average interest rate	Balance	% of total loans	Weighted average interest rate	Balance	% of total loans
Borrowings % of total loans	9.57%	2,628.62	99.53%	6.73%	2,503.72	98.95%
Net exposure to cash flow interest rate risk		2,628.62			2,503.72	

(iii) Sensitivity

Profit/loss is sensitive to higher/lower interest expense from borrowings as a result of changes in interest rates.

Particulars		Impact on Profit befo the FY endir		
	Increase/ Decrease in Basis Points	As at March 31, 2023	As at March 31, 2022	
INR	+50 - 50	13.14 (13.14)	12.52 (12.52)	

(b) Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The Company has no foreign currency loans in current year end and previous year. Therefore no sensitivity is provided.





(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)
CIN:U85110DL2008PLC174706
Notes to Consolidated Financial Information
(All amounts in million, unless otherwise stated)

(c) Price Risk

The company exposure to equity securities price risk arises from the investments held by company and classified in the balance sheet at fair value through profit and loss. The company does not have any investments at the current year end and previous year which are held for trading. Therefore no sensitivity is provided.

II. Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the Company. The company has adopted a policy of only dealing with creditworthy counterparties and obtaining sufficient collateral where appropriate as a means of mitigating the risk of financial loss from defaults. The company's credit risk exposure towards its counterparties are continuously monitored. Credit exposure of any party is controlled reviewed and approved by the appointed company official in this regard.

Trade receivables may be analysed as follows:

Age of receivables	As at March 31, 2023	As at March 31 2022
Within the credit period		7
1-180 days past due	882.85	680.04
181-365 days past due	220.04	230.97
more than 365 days	45.31	1.22
Total	1,148.21	912.22

III. Liquidity Risk

Liquidity risk is defined as the risk that company will not be able to settle or meet its obligation on time or at a reasonable price. The Company's objective is to at all times maintain optimum levels of liquidity to meet its cash and collateral requirements. The Company's management is responsible for liquidity funding as well as settlement management. In addition processes and policies related to such risk are overseen by senior management. Management monitors the company's net liquidity position through rolling forecast on the basis of expected cash flows.

The table below provides details regarding the remaining contractual maturities of financial liabilities at the reporting date based on contractual undiscounted payments:

Particulars	Within 1 year	1-3 years	More than 3 years	Total	Carrying amount
As at March 31, 2023					
Borrowings	631.82	1,084.08	921.86	2,637.76	2,637.76
Trade payables	168.78	-	-	168.78	168.78
Lease Liabilities	20.45	15.91	-	36.36	36.36
Other financial liabilities	142.40	-	-	142.40	142.40
Total	963.44	1,099.99	921.86	2,985.29	2,985.29

Particulars	Within I year	1-3 years	More than 3 years	Total	Carrying amount
As at March 31, 2022					
Borrowings	508.06	1,313.03	760.79	2,581.89	2,581.89
Trade payables	204.12	-	-	204.12	204.12
Lease Liabilities	19.12	36.74	-	55.85	55.86
Other financial liabilities	145.36	-	-	145.36	145.36
Total	. 876.66	1,349.77	760.79	2,987.23	2,987.24





(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

Note 31 (iii) Capital Management

(A) Risk Management

The Company manages its capital to ensure that the company will be able to continue as going concerns while maximising the return to stakeholders through the optimization of the debt and equity balance.

The Company's risk management committee reviews the capital structure of the Company on a semi-annual basis. As part of this review, the committee considers the cost of capital and the risks associated with each class of capital. The Company monitors capital on the basis of following gearing ratio, which is net debt divided by total capital plus debt.

(B) Gearing ratio

The gearing ratio at end of the reporting period was as follows.

Partciulars	As at March 31, 2023	As at March 31, 2022
Debt*	2,674.12	2,637.73
Cash and bank balances (including cash and bank balances in a disposal group held for sale)	374.32	117.07
Net debt	2,299.80	2,520.66
Total Equity#	1,829.64	1,168.85
Net Debts and Total equity	4,129.43	3,689.51
Net debt to equity ratio	55.69%	68.32%

^{*}Debt is defined as long-term and short-term borrowings including current maturities, books overdraft and lease liabilities. #Total equity (as shown in balance sheet) includes issued capital and all other equity reserves.





(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

32 Corporate Social Responsibility

As per Section 135 of the Companies Act, 2013, any company, meeting the applicability threshold, needs to spend at least 2% of its average net profit for the immediately preceding three financial years on corporate social responsibility (CSR) activities. The Board of Directors of the Company has approved the following expenditure on CSR activities.

Particulars	For the year ended 31-March-2023	For the year ended 31-March-2022
~Gross amount required to be spent during the year as per calculation specified for CSR activities	6.49	1.79
~Amount approved by the board to be spend during the year	6.49	3.00
~Amount spend during the year	6.70	3.00
~Shortfall at the end of year	-	

~Nature of CSR Activities

Amount during the year ended 31st March, 2023 & 31st March, 2022 has been paid to charitable society which works for health care of poor people.

The computation of CSR dues is based on the Profit and Loss, as made out on the basis of the already adopted accounts for the preceding financial years.

33 Disclosure as required under Notification No. G.S.R.(E) dated 4th September, 2015 as updated vide notification dated 22nd January 2019 issued by the Ministry of Corporate Affairs w.r.t MSME (As certified by the Management):

As per information available with the management, no supplier has declared MSME status. As such, this disclosure is not applicable.

Particulars	As at March 31, 2023	As at March 31, 2022
The principal amount and interest due thereon remaining unpaid to any supplier- MSME.		
~Principal	15.08	22.81
~Interest	0.13	0.18
The amount of interest paid by the buyer in terms of Section16 of the Micro Small and Medium Enterprise Development Act, 2006 (MSMED Act) along with the amounts of payment made to the suppliers beyond the appointed day during each accounting year.	7. 	-
The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed date during period) but without adding the interest specified under the MSMED Act.	-	
) The amount of interest accrued and remaining unpaid.	0.13	0.18
) The amount of further interest remaining due and payable even in the succeeding period, until such date when the interest dues above are actually paid to the small enterprise for the purpose of disallowance as a deductible		

expenditure under section 23 of the MSMED Act.





(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

34. Revenue from contracts with customers

Disaggregated revenue information

Set out below is the disaggregation of the Company's revenue from contracts with customers:

Particulars	For the year ended 31 March 2023	For the year ended 31 March 2022
Income from medical and healthcare services		
Revenue from hospital & pharmacy services Less: Inter Group Revenue	5,202.93	4,009.37
2000. Milet Group Revenue	5,202.93	4,009.37

Location of revenue recognition

All the business operations of the company are in India.

Timing of revenue recognition

Particulars	For the year ended 31 March 2023	For the year ended 31 March 2022
Services transferred at a point of time	553.56	515.76

No single customer represents 10% or more of the Company's total revenue during the years ended March 31, 2023 & March 31, 2022.

Reconciliation of revenue recognised with the contracted price is as follows:

Particulars	For the year ended 31 March 2023	For the year ended 31 March 2022
Contracted price	5,544.87	4,363.00
Reduction towards variable consideration components*		-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Discounts	(341.94)	(353.63)
Revenue recognised	5,202.93	4,009.37
*Variable consideration commonants in al. 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1:		.,

*Variable consideration components include discounts on the contract price.

Contract balances

Particulars	For the year ended 31 March 2023	For the year ended 31 March 2022	
Trade receivables*	1,148.21	912.22	
Contract liabilities (advance from patients)#	4.69	6.39	

Movement in contract liabilities during the year:

Particulars	For the year ended 31 March 2023	For the year ended 31 March 2022	
Balance at the beginning of the year	6.39	8.15	
Less: Revenue recognised from above	(6.39)	(8.15)	
Add: Addition during the year	4.69	6.39	
Balance at the end of the year	4.69	6.39	

^{*} Trade receivables are non-interest bearing and are generally on terms of 30 days.

Performance obligation

The revenue from OPD services and sale of Pharmaceutical products satisfies 'at a point in time' recognition criteria as prescribed by Ind AS 115.





[#] Contract liabilities include advances received from patients for hospital services pending final billing.

(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)
35. Borrowings
Details of borrowings availed by the company

S. No	Bank/ Financial Institution	Category of Loan	Interest Rate	Secuirty & Collateral provided	Repayment Terms	As at March 31, 2023	As at March 31, 2022
1	Indusind Bank	Equipment Loan	9.00%	Hypothecation created on the assets purchased out of the proceeds of the loan.		7.95	14.8
	Maximum amo	unt O/s during the year		ioan.	10 March -2024	(14.24)	(20.7
2	Indusind Bank	Equipment Loan	11.00%	Hypothecation created on the assets purchased out of the proceeds of the loan.	EMI of Rs. 4,99,637 payable for the period up to December -2023	3.94	9.2
	Maximum amo	unt O/s during the year				(8.85)	(13.7
3	Indusind Bank	Equipment Loan	11.00%	Hypothecation created on the assets purchased out of the proceeds of the loan.	EMI of Rs. 2,51,876 payable for the period up to December-2022		1.9
	Maximum amo	unt O/s during the year				(1.70)	(4.4
4	Kotak Mahindra Bank	Equipment Loan	10.00%	Hypothecation created on the assets purchased out of the proceeds of the loan.		-	5.2
	Maximum amo	unt O/s during the year				(3.86)	(19.6
5	SREI Equipment Finance Limited	Equipment Loan	12.00%	Hypothecation created on the assets purchased out of the proceeds of the loan.		8.12	17.7
	Maximum amo	unt O/s during the year			**************************************	(16.96)	(27.0
6	Punjab National Bank	Vehicle Loan	8.55%	Hypothecation created on the assets purchased out of the proceeds of the loan.	200 Met 100 Met	2.83	4.2
	Maximum amo	unt O/s during the year			,	(4.16)	(5.0
7	Axis Bank Ltd	Vehicle Loan	8.35%	Hypothecation created on the assets purchased out of the proceeds of the loan.	EMI of Rs. 1,83,999 payable for the period up to September, 2025	4.76	6.6
	Maximum amount O/s during the year					(6.52)	(8.1
8	Bank of Baroda	Vehicle Loan	7.45%	Hypothecation created on the assets purchased out of the proceeds of the loan.	EMI of Rs. 1,06,776 payable for the period up to February, 2026	3.32	4.2
	Maximum amo	unt O/s during the year				(4.26)	(5.1
9	HDFC Bank Limited	Vehicle Loan	8.00%	Hypothecation created on the assets purchased out of the proceeds of the loan.	EMI of Rs. 1,61,000 payable for the period up to October, 2022	(0.00)	1.0
	Maximum amo	unt O/s during the year				(0.88)	(2.6
10	HDFC Bank Limited	Vehicle Loan	9.10%	Hypothecation created on the assets purchased out of the proceeds of the loan.	and the second of the second o	0.85	1.3
	Maximum amo	unt O's during the year				(1.29)	(1.7
П	HDFC Bank Limited	Vehicle Loan	8.50%	Hypothecation created on the assets purchased out of the proceeds of the loan.		0.19	0.9
	Maximum amo	unt Os during the year				(0.87)	(1.5
12	HDFC Bank Limited	Vehicle Loan	10.00%	Hypothecation created on the assets purchased out of the proceeds of the loan.	EMI of Rs. 26,485 payable for the period up to June -2023	-	0.3
	Maximum amo	unt () s during the year		adpal Associ		A Tr(0.34)	(0.6
		4.	1	New Delhi		HINTER DE	Services

(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

35. Borrowings

Details of borrowings availed by the company

		,					- , = · · · · · · · · · · · · · · · · · ·
S. No	Bank/ Financial Institution Categ	gory of Loan	Interest Rate	Secuirty & Collateral provided	Repayment Terms	As at March 31, 2023	As at March 31, 2022
13	Kotak Mahindra Bank Bus	iness Loan	External Bench Mark+ 2.70%	Secured Loan	EMI of Rs. 12,07,018 payable for the period up to January, 2029	70.50	79.15
	Maximum amount O/s	during the year				(78.39)	(80.00)
14	State Bank of India Over Maximum amount O/s	rdraft/ Cash during the year	8.50%	Secured Loan		97.79 (100.00)	100.46 (100.46)
5	State Bank of India The Maximum amount O/s	erm loan during the year	8.50%	Secured Loan	EMI of Rs. 78,82,887	234.43 (303.67)	310.06 (329.40)
6	Maximum amount O/s	erm loan during the year :	8.50%	Secured Loan	EMI of Rs. 1,09,98,265	327.48 (424.11)	433.03 (460.00)
	84 19 ³		A.	**			. A J
7	State Bank of India Medica	al Equipment Loan	8.50%	Secured Loan	Total facility available is of Rs. 7 Crores but till 31st March, 2022 facility utilised for Rs. 4.67 Crores	39.08	46.79
	Maximum amount O/s	during the year				(50.91)	(46.79)
8	State Bank of India Medica	al Equipment Loan	9.25%	GECL	Total facility available is of Rs. 7 Crores but till 31st March, 2022 facility utilised for Rs. 4.67 Crores	265.00	-
	Maximum amount O/s	during the year				(265.00)	-
9	Indusind Bank Equip	oment Loan	11.00%	Hypothecation created on the assets purchased out of the proceeds of the loan.		66.91	-
	Maximum amount O/s	during the year				(72.50)	-
O	Punjab National Bank Veh	icle Loan	6.85%	Hypothecation created on the assets purchased out of the proceeds of the loan.		0.56	0.63
	Maximum amount () s	during the year		•	,	(0.62)	(0.66)
	Punjab National Bank Veh	icle Loan	6.85%	Hypothecation created on the assets purchased out of the proceeds of the loan.		0.56	0.63
	Maximum amount O/s	during the year				(0.62)	(0.66)
2	Punjab National Bank Veh	icle Loan	6.85%	Hypothecation created on the assets purchased out of the proceeds of the loan.		0.56	0.63
	Maximum amount () s o	during the year		0/(8/00/00)		(0.62)	(0.66)
				-21 Ac			





(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.) CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information (All amounts in million, unless otherwise stated)

35. Borrowings

Details of borrowings availed by the company

S. No	Bank/ Financial . Institution	Category of Loan	Interest Rate	Secuirty & Collateral provided	Repayment Terms	As at March 31, 2023	As at March 31, 2022
23	Punjab National Bank	Vehicle Loan	6.85%	Hypothecation created on the assets purchased out of the proceeds of the loan.		0.55	0.63
	Maximum amo	ount O/s during the year			1.0,011001, 2020	(0.61)	(0.66
24	Punjab National Bank Maximum amo	Vehicle Loan ount O/s during the year	6.85%	Hypothecation created on the assets	EMI of Rs. 9,980 payable	0.56 (0.62)	0.62 (0.65
25	Punjab National Bank Maximum amo	Vehicle Loan ount O/s during the year	6.85%	Hypothecation created on the assets	EMI of Rs. 32,000	1.83 (2.03)	2.05 (2.10
26	Punjab National Bank Maximum amo	Vehicle Loan ount O/s during the year	6.85%	Hypothecation created on the assets	EMI of Rs. 32,000	1.83 (2.03)	2.05 (2.10
27	Punjab National Bank	Term Loan	9.80%	Project loan taken for finishing of building and purchase of plant and equipment	Monthy payments of principals and interest as per the terms agreed with the banks. The entire loan amount to be paid by Sep, 2028	233.76	254.74
	Maximum amo	unt O/s during the year				(252.76)	(280.55
28	SREI Equipment Finance Limited	Equipment Loan	12.00%	Hypothecation created on the assets purchased out of the proceeds of the loan.		4.31	8.79
	Maximum amo	unt ()'s during the year				(8.45)	(12.69
29	Tata Capital Financial Services Ltd Maximum amo	Equipment Loan unt () s during the year	6.30%	Hypothecation created on the assets purchased out of the proceeds of the loan.	Amount of Rs 10,41,700/- plus applicable interest payable at monthly rest. The entire loan is to be cleared by the period Jan, 2026	39.58	51.65 (65.61)
30	Punjab National Bank	Term Loan :	9.25%	Working Capital Term Loan under Guaranteed Emergency Credit Line (GECL) 2.0	EMI of Rs 47,10,417/- plus applicable interest payable monthly starting from December, 2023 for the period up to Dec - 2027.	226.01	225.95
	Maximum amo	unt Os during the year			:F177 (U	(227.40)	(226.10)
31	Punjab National Bank	Term Loan	9.80%	Land & Building of the Project and personal properties and guarantees of the promoters. Term loan has been taken over by Punjab National bank from The Nainital Bank in December,2021.	Monthy payments of principals and interest as per the terms agreed with the banks. The entire loan amount to be paid by April,2027	393.45	443.92
	Maximum amo	unt O/s during the year				(446.40)	(455.60)
				nal Ase			





(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.) CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information (All amounts in million, unless otherwise stated)

35. Borrowings

Details of borrowings availed by the company

S.	Bank/ Financial Institution	Category of Loan	Interest	Secuirty & Collateral provided	Panayment Town-	1	
	Institution		Rate	conateral provided	Repayment Terms	As at March 31, 2023	As at March 31, 2022
32	Punjab National Bank Maximum amo	Term Loan ount O/s during the year	9.80%	Project loan taken for finishing of	Monthy payments	20.88 (29.63)	- L
33		Equipment Loan	8.25%	Hypothecation created on the assets purchased out of the proceeds of the loan.	Amount of Rs 1,68,260/- plus applicable interest payable at monthly rest. The entire loan is to be cleared by the period Aug, 2026	5.88	
	Maximum amo	unt O/s during the year				(6.86)	=
34	Punjab National Bank	Overdraft/ Cash Credit Facility	9.80%	Secured Loan		43.65	2
	Maximum amoi	unt O's during the year				(50.00)	12
35	Tata Capital Financial Services Ltd		10.50%	Hypothecation created on the assets purchased out of the proceeds of the loan.	Amount of Rs 6,58,629/- plus applicable interest payable at monthly rest. The entire loan is to be cleared by the period Nov, 2027	28.67	
36	Tata Capital Financial	Equipment Loan on O's during the year	10.50%	Hypothecation created on the assets	Amount of Rs 49,131/-	(41.22) 2.14 (2.14)	,
37	Punjab National Bank <i>Maximum amou</i>	Term Loan nt O/s during the year	10.80%	Hypothecation created on hospital land & building situated at Orcha, Jhansi		481.62	504.85
38	Punjab National Bank	Term Loan	10.80%	Hypothecation created on hospital land & building situated at Orcha, Jhansi		21.51	(504.85)
39	Dr. Ajay Kumar Tyagi	nt O's during the year		Unsecured Loan		(50.00)	8.70
10	Dr. Kapil Kumar <i>Maximum amour</i>	nt O/s during the year		Unsecured Loan		(8.70) - (10.44)	(8.70) 10.44 (10.44)
4 1	Yatharth Tyagi <i>Maximum amour</i>	nt () s during the year		Unsecured Loan		(32.50)	32.50 (32.50)





(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

36. Related Party Transactions

a) Names of the related parties and description of relationship:

Key managerial personnel (KMP) of Holding Company

Yatharth Hospital & Trauma Care Services Limited

- 1. Dr. Ajay Kumar Tyagi
- 2. Dr. Kapil Kumar
- 3. Dr. Neena Tyagi
- 4. Dr. Manju Tyagi
- 5. Mr. Yatharth Tyagi
- 6. Dr. Sanjeev Upadhyaya
- 7. Mr. Mukesh Sharma
- 8. Dr. Ila Patnaik
- 9. Mrs Promila Bharadwaj
- 10. Mr Ritesh Mishra
- 11. Mr. Amit Kumar Singh
- 12. Mr. Pankaj Prabhakar

Key managerial personnel (KMP) of Subsidiary Company

a) AKS Medical & Research Private Limited

- 1. Dr. Ajay Kumar Tyagi
- 2. Dr. Kapil Kumar
- 3. Dr. Neena Tyagi
- 4. Dr. Manju Tyagi
- 5. Dr. Sanjeev Upadhyaya

b) Sanskar Medica India Limited

- 1. Dr. Ajay Kumar Tyagi
- 2. Dr. Kapil Kumar
- 3. Dr. Neena Tyagi
- 4. Dr. Manju Tyagi

c) Ramraja Multispeciality Hospital & Trauma Centre Private Limited

- 1. Dr. Ajay Kumar Tyagi
- 2. Dr. Kapil Kumar
- 3. Dr. Pradeep Jain
- 4. Mayank Gupta
- 5. Alka Jain
- 6.Dr. Ila Patnaik
- 7.Mrs Promila Bharadwaj

Relative of key managerial personnel

- 1. Mr. Sanskar Tyagi
- 2. Mr. Lal Chand Tyagi
- 3. Mrs. Shilpi Singh

Enterprise exercising significant influence on the Company

Nil

Enterprises where key managerial personnel along with their relatives exercise significant influence No such enterprise



Nature of Relationship

Chairman

Managing Director

Director (upto 31.08.2021)

Director (upto 31.08.2021)

Director (w.e.f. 15.09.2021)

Independent Director (w.e.f. 21.02.2022)

Independent Director (w.e.f. 21.02.2022)

Independent Director (from 21.02.2022 to 02.08.2022)

Independent Director (w.e.f. 22.10.2022)

Company Secretary & Compliance Officer

Chief Executive Officer (w.e.f. 15.09.2021)

Chief Financial Officer (w.e.f. 21.02.2022)

Nature of Relationship

Director

Director

Director

Director

Independent Director (w.e.f. 07.03.2022)

Director

Director

Director

Director

Director (w.e.f. 28.01.2022)

Director (w.e.f. 28.01.2022)

Director (upto 18.02.2022)

Director (upto 18.02.2022)

Director (upto 18.02.2022)

Independent Director (w.e.f 07.03.2022 to 02.08.2022)

Independent Director (w.e.f. 12.11.2022)



(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

(b) Following is the summary of significant related party transactions during the year:

	For the year ended 31 March 2023	For the year ended 31 March 2022
Remuneration to KMPs & Relatives of KMPs		
Dr. Ajay Kumar Tyagi	12.00	12.00
Dr. Kapil Kumar	12.00	12.00
Dr. Manju Tyagi	12.00	12.00
Dr. Neena Tyagi	12.00	12.00
Mr. Yatharth Tyagi	12.00	7.00
Mr. Sanskar Tyagi	-	
Mr. Ritesh Mishra- Company Secretary	0.78	0.78
Mr. Amit Kumar Singh	2.38	1.32
Mr. Pankaj Prabhakar	2.85	0.48
Mrs. Shilpi Singh	1.46	-
		40
Rent paid to KMP		
Dr. Ajay Kumar Tyagi	-	-
Dr. Kapil Kumar	-	-
Dr. Manju Tyagi	-	-
Dr. Neena Tyagi	-	-
Director sitting fees paid	0.20	0.10
Mr. Mukesh Sharma	0.30	0.18
Dr. Ila Patnaik	-	0.18
Mrs Promila Bharadwaj	0.30	-
Dr. Sanjeev Upadhyaya	0.14	-
Investment in Equity Shares		
AKS Medical & Research Centre Private Limited	_	-
Ramraja Multispeciality Hospital & Trauma Centre Private Limited		37.71
Purchase of Equity shares of (AKS) Dr. Ajay Kumar Tyagi	_	56.64
Purchase of Equity shares of (AKS) Dr. Kapil Kumar	_	32.56
Turchase of Equity shares of (ARS) Dr. Raph Ruman		32.30
Loans and Advances- Subsidiary Company		
AKS Medical & Research Private Limited		
Loans and Advances- Received	428.60	633.53
Loans and Advances- Paid Back	560.79	503.44
Loans and Advances- Given	÷	
Loans and Advances- Received Back	-	-
Sanskar Medica India Limited		
Loans and Advances- Received	_	_
Loans and Advances- Received Loans and Advances- Paid Back		
Loans and Advances-1 and Dack		
Loans and Advances- Given	0.05	<u>-</u>
Loans and Advances- Received Back	-	-
Ramraja Multispeciality Hospital & Trauma Centre Private Limited		
Loans and Advances- Given	153.37	268.34
Loans and Advances- Received Back	14.54	-
214	8 Trau	mac
agpal Asso	137	107
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	- A	100
(New Melhi) (8)		CP.
(* (New Delhi) %	5/61	151
18/ 18/	18	155
Q ₁	1181	101

(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

Loans and Advances received fro	n KMP's & Relatives of KMP's
---------------------------------	------------------------------

Dr. Ajay Kumar Tyagi		
	(8.70)	0.70
Dr. Kapil Kumar	(0.70)	8.70
Yatharth Tyagi	(10.44)	10.44
ruman ryagi	(32.50)	32.50

c) The Company has the following amounts due from/ to the related parties:

amounts due from/ to the related parties:		
_	As at 31 March 2023	As at 31 March 2022
Borrowings (Current)		
AKS Medical & Research Private Limited		
Sanskar Medica India Limited	-	130.09
Dr. Ajay Kumar Tyagi	56.10	56.10
Dr. Kapil Kumar	-	8.70
Yatharth Tyagi	-	10.44
	-	32.50
Amount Receivable		
Sanskar Medica India Limited	1.11	
Ramraja Multispeciality Hospital & Trauma Centre Private Limited	1.11	1.06
AKS Medical & Research Private Limited	407.17	268.34
	2.09	5
Remuneration payable to KMP		*
Dr. Ajay Kumar Tyagi		
Dr. Kapil Kumar		0.73
Mr. Yatharth Tyagi		1.39
Mr. Ritesh Mishra- Company Secretary	0.06	0.16
Mr. Amit Kumar Singh	0.00	0.06
Mr. Pankaj Prabhakar	0.18	-
Mrs. Shilpi Singh	0.22	0.05
Dr. Neena Tyagi	0.01	
Dr. Manju Tyagi	-	4.22
	-	6.59
Director sitting fees payable		
Mr. Mukesh Sharma	0.13	0.12
Dr. Ila Patnaik	-	0.12
Mrs Promila Bharadwaj	0.16	0.12
Dr. Sanjeev Upadhyaya	0.13	72
	5110	-

d) All transactions with these related parties are at arm's length basis and resulting outstanding receivables and payables including financial assets and financial liabilities balances are settled in cash. None of the balances are secured. (All the amounts of transactions and balances disclosed in this note are gross and undiscounted.)





(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)
CIN: U85110DL2008PLC174706
Notes to Consolidated Financial Information

Note 37: Employee benefit plans

The employee benefit schemes are as under: Defined Retirement Plans (1) Provident Fund

The benefit of Provident Fund is extended to all such eligible employees, as is defined under the relevant regulations under the applicable the provisions of Provident Fund Act and the Rules and ESIC. Amount debited to Profit and Loss account including Administrative and Employees Deposit Linked Insurance charge and ESIC amounts to Rs 2.03/- during the period (FY- 2021-22 - Rs 0.74/-).

Gratuity - The liability for Gratuity is provided on the basis of Actuarial Valuation made at the end of each financial year. The Actuarial Valuation is made on Projected Unit Credit method as per Ind AS 19.

Reconciliation of opening and closing balances of the present value of the defined benefit obligation:

		For the year ended	For the year ended
Opening defined benefit obligation		31 March 2023	31 March 2022
Current service cost	x**	9.83	0.46
Interest Cost	. 13	7.09	13.11
Actuarial (gain)/loss		0.67	0.03
Benefits paid		(4.01)	(3.77)
Benefit obligation at the end of the year		13.57	9.83
Provision (Current) Refer Note No22		0.50	0.05
Provision (Non- Current) Refer Note No16		0.59 12.99	0.05 9.78
Gratuity expense recognised in the statement of profit and loss			
		For the year ended 31 March 2023	For the year ended 31 March 2022
Current service cost		7.09	13.11
Interest on defined benefit obligation		0.67	0.03
Net actuarial (gain)/loss recognised in the year		-	0.03
Net gratuity expenses		7.75	13.14
Re-measurements recognised in other comprehensive income			
		For the year ended	For the year ended
Actuarial (gain)/loss on defined benefit obligation		31 March 2023	31 March 2022
Return on plan assets excluding interest income		(4.01)	(3.77)
Actuarial (gain)/loss recognised in other comprehensive income			
		(4.01)	(3.77)
Summary of actuarial assumptions Financial assumptions at balance sheet date:			
· · · · · · · · · · · · · · · · · · ·			
*	•	For the year ended 31 March 2023	For the year ended 31 March 2022
Discount rate		7.30	6.75
Salary escalation rate Attrition rate		5.00%	5.00%
	Age 18 to 30	13.00%	13.00%
	Age 30 to 45	13.00%	13.00%
	Above 45 Years	13.00%	13.00%
Retirement Age		60 Years	60 Years
Maturity profile of defined benefit obligation			
		For the year ended	For the year ended
st following year		31 March 2023	31 March 2022
/car 2 to 5		0.59	0.05
'car 6 to 10		7.15	1.99
More than 10 years		10.37	8.63
ANA AND AND AND AND AND AND AND AND AND		7 44	

Discount rate: The discount rate is based on the prevailing market yields of Indian government securities as at the balance sheet date for the estimated term of the obligations.

Salary escalation rate: The estimates of future salary increases considered takes into account the inflation, seniority, promotion and other relevant factors.

Sensitivity analysis: Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant would have affected the defined benefit obligation by the amounts shown below

Discount rate	(100 bps movement)	

Salary escalation rate (100 bps movement)

For the year ended	31 March 2023	For the year ended 31 March 2022	
Increase	Decrease	Increase	Decrease
9.82	11.35	7,50	9.03
11.24	9.92	9.04	7.48

Expected contributions to the plan for the next annual reporting period

Expected contributions to the plan for the next annual reporting period



For the year ended	For the year ended
31 March 2023	31 March 2022



Annexure VI Notes to Consolidated Financial Statements

38. Contingent Liabilities

a) Bank & Corporate Guarantees

Particulars	As on 31st March, 2023	As on 31st March, 2022
Bank Guarantees (BG)	109.24	90.79
Margin Money against above BG	23.28	16.19
Corporate Guarantee (CG)	2885.37	1390.60
Outstanding against the above CG	2249.20	1154.10

b) Other contingent liabilities

- i. A case has been filed within the jurisdiction of Gautam Budh Nagar, Uttar Pradesh against a director and the doctors of the company for medical negligence. The opponent party has not specified any compensation for the said alleged medical negligence.
- ii. First Information Report dt. November 19, 2022 has been filed against the doctors and the management of the Company for medical negligence. The quantum in the case instant is not yet ascertained.

Note:- For all the contingent liabilities mentioned hereinabove, the Company believes that it is not liable to pay any amount and has not provided any sum for these liabilities in its books of accounts. The Company is dealing with these cases at appropriate legal forum

c) Capital Commitments

- The group has been allotted Plot No- NH-31 in Sector Omega-1, Greater Noida by Greater Noida Industrial Development Authority (GNIDA) for a total amount of Rs. 76.27 million on 18th March, 2023. The group has already deposited Rs. 6.41 million by 31st March, 2023. Further the balance was to be paid within 90 days from the date of issue of allotment letter which has already been paid by the group.
- ii) The group has capital commitments of Rs 344.45 million (net of advance paid) (previous year Rs 326.60) for purchase of hospital equipment.
- The group has imported Capital Goods under Export Promotion Capital Goods Scheme [EPCG], where-under the Company is required to fulfil export obligation/deemed exports amounting to R\$ 62.36 million [Previous Year `Nil]. The liability amounting to

Annexure VI Notes to Consolidated Financial Statements

Rs 62.36 million [Previous Year Nil] on account of custom duty may arise along with interest @15% p.a., in the event of non-fulfilment of export obligation. The group has completed export obligation amounting to Rs NIL upto end of this financial year and submitted the relevant documents with Director General Foreign Trade for seeking fulfilment of export obligation certificate.

- 39. There is no impairment loss on fixed assets on the basis of review carried out by the management in accordance with IND AS 36.
- 40. Balances of certain trade receivables, loans & advances, advances received from customers and trade payables are subject to confirmation, if any. The management does not expect any material difference affecting the financial statements on such adjustments.

41. Covid 19 business and government guidelines

During the financial year 2022-23, the group has not treated any patient infected with Covid-19, whereas during the financial year 2021-22 the company had admitted and treated Covid-19 infected patients. There has been government guidelines related to the treatment and the cost of treatment of Covid 19 Patients. The Company has followed all such guidelines.

42. Foreign exchange earning and outgo

a) Foreign exchange earnings & outgo is as follows:

Particulars	31st March, 2023	31st March, 2022
Cost of Medical Equipment	41.21	= x
Income in Foreign Exchange	3.21	. =
Advance for Purchase of Medical Equipments	-	3.00

43. Covid 19 and grant for moratorium to pay principal and interest on outstanding loan

During the financial year 2019-2020 and 2020-2021, Covid 19 affected the overall business cycle of the economy. To address to liquidity concern of the businesses, the Reverse Bank of India wide its circulars; DOR.No.BP.BC.47/21.04.048/2019-20 March 27,2020, Circular DOR.No.BP.BC.63/21.04.048 /2019-20 April 17, 2020, DOR. No.BP.BC.71/21.04.048/2019-20 May 23, 2020, allowed the moratorium to pay the due principal and interest on outstanding loans. The Company availed the Abenefits of given moratorium to the extent of Rs. 121.77

Annexure VI Notes to Consolidated Financial Statements

Millions (inclusive of principal and interest). The amount covered under the moratorium shall be paid by extending the overall term of the respective loan account.

44. Income Tax

The major components of income tax expenses are as follows:

Particulars	As at 31st March, 2023	As at 31st March, 2022
Income Tax Expense		
Current Tax:		
Current Income Tax	246.66	180.09
Income tax of earlier year	1.61	-
MAT credit entitlement/reversed	11.03	18.02
Deferred Tax	(40.19)	(8.68)
TOTAL	219.10	189.44

The income tax expense for the year can be reconciled to the accounting profit/(loss)as follows:

Particulars	As at 31st March,	
Profit / (Loss) before tax as per Statement of Profit and Loss	2023 876.78	631.06
Effective Tax Rate Tax Effect of:	25.17%	29.12%
Income tax using the Company's domestic tax rate Tax Effect of:	220.69	183.76
Timing Difference- Deferred Tax	(40.19)	(8.68)
Permanent Difference	3.19	(5.67)
Total Income Tax expenses recognized in profit and Loss account	219.10	189.44
Effective Tax Rate (%)	24.99%	30.02%





(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.)

CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

45. Ratios as per Schedule III requirement

Current Ratio		2022-23	2021-
Numerator	Current Assets	1 762 67	1 201
Denominator	Current Liabilities	1,762.67	1,094.0
Ratio		995.18	971.0
%Change		1.77	1.1
Reason for change: Relative increase in cash preferred to payoff its creditors and thus impr	& cash equivallent & increase in debtors in tendem with increase in Sale, has led to high	er current ratio. During the period	od company
S 9	sing the eartest ratio.		
Debt Equity Ratio Numerator			
Denominator	Long Term Borrowings + Short Term Borrowings	2,637.76	2 501 (
	Shareholders Funds	1,829.64	2,581.3
Ratio		1.44	1,168.5
%Change		-34.73%	2.2
Reason for change: Increased profits added to	to shareholders fund at the same time Co did not increase its much of itsdebt, thus leading	to better Debt Equity Ratio	
Debt Service Coverage Ratio	,	To contact Debt Equity Ratio.	
Numerator	EBIDTA		
Denominator		1,337.65	1,108.1
Ratio	Principal repayments of Long term borrowings & Interest	632.94	508.8
%Change		2.11	2.1
		-2.96%	
Return on Equity/ Investment Ratio	8.		
Numerator	*		
Denominator	Net Profit after Taxes	657.68	441.6
Ratio	Shareholder's Equity	1,829.64	1,168.8
		35.95%	
%Change		-4.86%	37.78
Investor T			
Inventory Turnover Ratio			
Numerator	Sales	5,202.93	4.000.20
Denominator	Average Inventory		4,009.3
Ratio	,	56.33	42.93
%Change		92.37	93.40
		-1.10%	
Trade Receivables Turnover Ratio			
Numerator	Net Credit Sales	5 202 02	4.000.0
Denominator	Avg Accounts Receivable	5,202.93	4,009.37
Ratio		965.91	611.52
%Change		5.39	6.56
		-17.84%	
Frade Payables Turnover Ratio			
Numerator	Net Credit Purchases	222.22	
Denominator	Avg Trade Payables	929.35	813.28
Ratio	B Trade Layabres	186.45	184.73
%Change		4.98	- 4.40
5		13.22%	
et Capital Turnover Ratio			
umerator	Net Sales	Warran and and	
enominator		5,202.93	4,009.37
tatio	Working Capital (Current Assets- Current Liabilities)	767.49	122.95
successful to the second control of the seco		6.70	20.44

Reason for change: The Current ratio on account of additions in debtors and cash & cash equivallent and at the same time paying creditors with better pending creditor days, has led to better current ratio. This has led to better working capital as compared to sale.

Net Profit Ratio

%Change

Numerator Net Profit 657.68 441.62 Denominator Net Sales 5,202.93 Ratio 4,009.37 12.64% 11.01% %Change 14.76%

Return on Capital Employed

Numerator Denominator Ratio %Change



Earning before Interest and Taxes Capital Employed

13	1,062.33 4,467.39	201	815.78 3,750.73
18	23.78%	100	21.75%
1	9.33%	131	
151	A J	15	

6.78

-79.21%

32.61

(Formerly Known as Yatharth Hospital & Trauma Care Services Pvt. Ltd.) CIN:U85110DL2008PLC174706

Notes to Consolidated Financial Information

(All amounts in million, unless otherwise stated)

46. Business Combination and Goodwill

The Company has acquired equity shares of;

- (1) AKS Medical & Research Centre Pvt Ltd (AKS) and
- (2) Ramraja Multispecialty Hospital & Trauma Centre Pvt. Ltd. (Ramraja)

AKS became 100% subsidiary on September 20th 2016. Later on, though AKS remained subsidiary of the Company, to augment its capital requirements, AKS issued equity shares to Promoters and other entities. Over a period of time to gain better control and avoid any conflict of interest, the Company acquired shares of AKS from the minority shareholders; the Promoters and non Promoter entities. The valutations of AKS was based on the valuation report of the registered valuer.

* *	For the year ended March 31, 2023	For the year ended March 31, 2022
Number of equity shares acquired/held	4.070.000	
Consideration paid (Rs million)	4,079,000	4,079,000
% of Controling stake	89.20 100.00%	89.20 100.00%
Value of Assets acquired (based on audited financial statements of preceeding year)		
Property Plant & Equipment (incl CWIP)	1,183.05	1,183.05
Current Assets other than cash & bank	107.95	107.95
Cash & cash equivallent	43.69	43.69
Total Value of assets acquired	1,334.69	1,334.69
Total Value of Liabilities acquired (based on LY audited financial statements)		
Bank borrowings	768.37	768.37
Other liabilities	149.28	149.28
Total Value of libailities assumed	917.66	917.66
Net Asset Value for the equity shares acquired from the minority shareholders	82.27	92.27
Amount paid for Goodwill	6.93	82.27 6.93
	0.93	0.93
Total Purchase Consideration paid to minority shareholders	89.20	89.20
Cumulative amount paid for the Goodwill (A)	11.05	11.05

Ramraja became 100% subsidiary on February 18th 2022. The valuation of Ramraja was arrived based on the valuation report of the regsitered valuer and the negotiations carried out between the Company and the erstwhile shareholders of the Company.

	For the year ended March 31, 2023	For the year ended March 31, 2022
Number of equity shares acquired/held	4010 000	4.010.000
Consideration paid (Rs million)	4,010,000	4,010,000
% of Controling stake	37.71 100%	37.71 100%
Value of Assets acquired		
(based on provision financial statements on the date of acquisition)		
Property Plant & Equipment (incl CWIP & intangibles)	310.05	310.05
Current Assets other than cash & bank	0.05	0.05
Other assets- including deferred tax	103.84	
Cash & cash equivallent	115.30	115.30
Total Value of assets acquired	529.24	529.24
Total Value of Liabilities acquired (based on LY audited financial statements)		9 g 5 e
Bank borrowings (including interest)	500.00	500.00
Other liabilities	377.49	377.49
Total Value of libailities assumed	877.49	877.49
Net Asset Value for the equity shares acquired from the minority shareholders	(348.25)	(348.25)
Amount paid for Goodwill	385.96	385.96
Total Purchase Consideration paid to minority shareholders	37.71	37.71
Cumulative amount paid for the Goodwill (B) Total value of Goodwill carried as on the data (ALP)	385.96	9. Maurila 385.96
(80)	/-	190
Total value of Goodwill carried as on the date (A+B)	397.04	397:01
Aloundaria (a)	30	1 13

Annexure VI Notes to Consolidated Financial Statements

47. Details related to borrowings secured against current assets:

The company has given current assets (trade receivables and inventories) as security for working capital (fund and non fund-based limits) obtained from State Bank Of India & Punjab National Bank. This is applicable for year ended 31st March 2023 and 31st March 2022. The Company submitted the required information with the bank and the required reconciliation is presented below:

For the period ending March 31st 2023

Nature of current assets offered as security	Quarter	Amount disclosed as per statement	Amount as per books of accounts	Variance	Remarks
Inventories and trade receivables	Q1 FY 2022-23	1311.45	1300.42	11.03	Minor difference while finalization of accounts.
Inventories and trade receivables	Q2 FY 2022-23	1167.06	1126.7	40.36	Stock of otherwise consumable items were included in the stock submitted to bank.
Inventories and trade receivables	Q3 FY 2022-23	1,225.20	1,225.20	_	-
Inventories and trade receivables	Q4 FY 2022-23	1054.95	1208.9	(153.95)	The statement to bank was submitted with data as at March 28th 2023, and therefore the variance.

For the period ending March 31st 2022

Nature of current assets offered as security	Quarter	Amount as per books of accounts	Amount as per books of accounts	Variance	Remarks
Inventories and trade receivables	Q1 FY 2021-22	· NA	NA	NA	. 4
Inventories and trade receivables	Q2 FY 2021-22	NA	NA	NA	-
Inventories and trade receivables	Q3 FY 2021-22	NA	NA	NA	-
Inventories and trade receivables	Q4 FY 2021-22	964.17	964.17	Nil	- Svolin

Annexure VI Notes to Consolidated Financial Statements

48. Other Statutory information

- a) The group does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.
- b) The group does not have any transactions with companies struck off.
- c) The group does not have any charges or satisfaction which is yet to be registered with Registrar of Companies beyond the statutory period.
- d) The group has not traded or invested in Crypto currency or Virtual Currency for the year ended March 31, 2023 and March 31, 2022.
- e) The group has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
 - i. directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the group (Ultimate Beneficiaries); or
 - ii. provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
- f) The group has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the group shall:
 - i. directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries); or
 - ii. provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries,
- g) The group has no such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).
- 49. The parent company had filed Draft Red Herring Prospectus (DRHP) with SEBI on 31st March, 2022 for the fresh issue of capital amounting to Rs. 6,100 Million and Offer for Sale (OFS) of 6,551,690 equity shares. Based on submissions made in the DRHP and other clarifications provided by the company, SEBI has issued The Observation Letter on 02nd August, 2022, enabling the company to proceed further for the issue of fresh capital and OFS. To the extent provided under relevant SEBI regulations the Company has option to change the quantum of fresh issue of capital and/ or the OFS as the case may.

Annexure VI Notes to Consolidated Financial Statements

- 50. Name of the parent company has been changed from Yatharth Hospital & Trauma Care Services Private Limited to Yatharth Hospital & Trauma Care Services Limited during the financial year 2021-22
- The previous year figures have been regrouped /reclassified to confirm with the current year 51. requirements.
- 52. These Consolidated Financial Statements were approved by Board in its Meeting held on 17/06/2023 at Noida.

As per our report of even date attached

For R. Nagpal Associates **Chartered Accountants**

Firm Registration No.: 002626N

New Delh

For and on behalf of the Board of Directors Yatharth Hospital & Trauma Care Services Limited

(Rohit Mehra)

Partner

M. No.: 093910 Place: Noida

Date: 17/06/2023

Dr Ajay Kumar Tyagi

Dr Kapil Kumar Chairman & Whole-Time **Managing Director**

TraumaDIN: 01818736

Pankaj Prabhakar

Director

DIN:01792886

CS & Compliance Officer

M. No 51166

PAN No.- AGFPP2937

CFO